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Abstract
The principle obstacle to successful organ transplantation is the failure of 
modem immunosuppressive protocols to result in indefinite allograft survival 
and the concurrent side effects of such protocols such as infection and 
malignancy. As a means of overcoming these difficulties monoclonal antibodies 
have been used experimentally and in clinical practice to target specific 
molecules involved in the rejection response in the hope that operational 
tolerance to a graft can be induced by a short peri transplant treatment. The 
central role of the a/(3 T cell receptor in allorecognition and graft rejection 
makes it an ideal target for intervention.
In this thesis, experiments were carried out using a monoclonal antibody to the 
rat a /p  T cell receptor (R73) to investigate its action in a model of rat 
heterotopic cardiac transplantation.
In preliminary experiments, the mouse IgGl monoclonal antibody R73 was 
administered intraperitoneally at a dose of 200jig on days -2 and -1 relative to 
receiving a fully allogeneic heart graft (transplantation taking place on day 0). 
Prolongation of heart graft survival was seen in the BN-Lewis strain 
combination however indefinite graft survival (>100days) was only obtained in 
the Lewis-DA strain combination. In order to obtain the optimal treatment 
regime in this strain combination, antibody doses of 50jig, 200pg and 500pg 
were administered to separate groups. 200pg and 500pg doses produced
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permanent graft survival and so the 200pg dose on days -2 and -1 was used in 
all further experiments. A group of animals underwent thymectomy prior to 
transplantation under cover of R73. The majority of animals accepted their 
grafts permanently, suggesting a peripheral mechanism of action for R73. This 
was further supported by the observation that exogenous EL-12 administered 
after heart transplantation to R73 treated animals resulted in reduced graft 
survival.
Studies were then carried out to evaluate the effect of R73 on the peripheral T 
cell pool. Flow cytometric analysis of lymphocytes in the peripheral blood and 
lymph nodes of R73 treated graft recipients revealed marked depletion of CD4 
and CD8 T cells at days 4 and 7 post transplant with reconstitution of the T cell 
pool by day 21. Depletion was not complete, however, and 50% of T cells 
were present at day 7. Delaying heart grafting until this time still resulted in 
indefinite graft survival in the majority of recipients. This would suggest that 
R73 treatment not only partially depletes peripheral T cells but also renders the 
remaining cells unresponsive or results in the emergence of a regulatory 
population of cells. Flow cytometry also revealed the presence of T cell 
receptor modulation after R73 treatment. Immunohistochemical staining of the 
heart grafts themselves was also carried out at day 7 post transplant in R73 
treated and rejecting control animals. This revealed a marked reduction in the 
graft infiltrate of R73 treated hearts compared to rejecting untreated hearts.
In further in vitro experiments, lymph node cells from R73 treated graft 
recipients were harvested at various time points post transplant and stimulated
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in allogeneic MLR. Cells from treated animals failed to proliferate at day 4 post 
transplant but proliferated normally at days 7, 21 and 100 to both allogeneic 
and third party stimulators. Analysis of the cytokines in the supernatants of the 
MLR’s revealed reduced IL-2 production by R73 treated LNC compared to 
rejecting animals and this was observed even as long as 100 days post 
transplant. Cytokine gene transcripts detected by RT-PCR in the grafts 
removed from R73 treated and rejecting animals revealed reduced IL-2 and 
IFNy gene transcription in treated animals but comparable production of IL-4, 
IL-10 and IL-13. It would seem therefore that the cells which remain after R73 
treatment are unable to produce IL-2 normally and the absence of this critical 
cytokine may be an important mechanism in the action of R73.
Finally, experiments were carried out to investigate whether R73 ligation of the 
TCR would result in alterations in apoptotic activity in graft recipients. 
Propidium iodide staining and flow cytometric analysis of LNC revealed 
increased apoptotic activity in the lymph nodes of R73 treated graft recipients 
at day 7 post transplant compared to rejecting and normal animals. This 
increased activity depended on the presence of a heart graft as DA animals 
given R73 alone displayed baseline apoptotic activity. Interestingly, TUNEL 
staining of heart grafts from R73 treated and rejecting animals revealed 
increased apoptotic activity in the heart grafts of rejecting animals suggesting 
that apoptosis occurs both as a tolerogenic mechanism perhaps by altered 
signalling via the TCR and as a mechanism of graft destruction by infiltrating T 
cells.
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CHAPTER ONE 
Introduction and review of the current literature
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1.1 History and current state of solid organ transplantation
The latter half of the 20th century has seen the emergence of solid organ 
transplantation as the treatment of choice for patients with end stage disease 
affecting the kidneys, liver, heart, lungs and pancreas. As a result, thousands of 
patients each year now have an alternative to either long term artificial organ 
support or death and as the experience of specialist centres increases, more and 
more patients each year are being considered candidates for organ 
transplantation.
Tissue grafting has been carried out both in the plant world and experimentally 
in animals for centuries, in fact the word “graft” was coined in the 16th century 
from the Greek word “greife”, the tool used to perform plant grafting. 
Interestingly, it was noted even in this early age that strict conditions were 
required for successful grafting between plants. Boronio in 1804 described the 
first experimental skin grafts in sheep, however long term graft success was 
exceptional. Successful autologous split skin grafting was first carried out by 
the surgeons Reverdin, Thiersch and Oilier at the end of the 19th century and 
although allografting and xenografting was attempted at this time they were 
unsuccessful.
Solid organ transplantation was shown to be technically possible in large animal 
models as far back as the turn of the century, and in 1933 the first human
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kidney allograft was carried out by the Ukranian surgeon Yu Yu Voronoy 
(Voronoy, 1936). Long term graft function was achieved in 1954 with the 
transplantation of a kidney between identical twin brothers in Boston and long 
term allograft function obtained in Paris in 1960 with the aid of 
immunosuppression (Hume et al, 1955, Serevelle et al 1951). With current 
immunosuppressive protocols one year graft function in the region of 80-90% 
is attainable in kidney, liver, heart, lung and pancreas transplantation.
The technical success of solid organ transplantation is mainly due to the work 
of the surgeons Alexis Carrel (1875-1944) and Mathieu Jaboulay (1860-1913) 
who developed techniques for vascular anastomoses allowing experimental 
transplantation to be carried out in animal models. In 1902 the first renal 
transplants in animals were carried out independently by Carrel and the 
Austrian surgeon Emerich Ullman. Carrel went on to carry out experiments 
using heart, lung and intestinal grafts (Carrel and Guthrie 1905). In 1906 
Jaboulay attempted the first renal transplant in man, grafting the kidney of a 
recently killed pig onto the elbow of a woman with nephrotic syndrome. The 
graft had to be removed on the 3rd day and did not function. Voronoy in 1933 
transplanted the kidney of a cadaver onto the thigh of a woman in acute renal 
failure but again the graft failed to function adequately and was removed on 
day 6. In 1954, however, the first successful human kidney allograft was 
carried out between identical twins at the Brigham hospital in Boston (Murray 
et al 1955). This event greatly encouraged the field of transplantation to
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progress but emphasised the necessity for tissue compatibility at this time. In 
1958 the first renal transplant under immunosuppression was carried out at the 
Brigham in Boston using total body irradiation and bone marrow 
transplantation. Although the graft functioned and did not show signs of 
rejection, the patient died of marrow suppression. 1960 saw the first successful 
transplant of a kidney between non twin siblings under cover of steroids. In this 
year, the first unrelated kidney transplants were carried out using total body 
irradiation and 6-mercaptopurine as immunosuppression. This event provided 
the justification for the continuation of clinical trials of renal transplantation and 
immunosuppressive protocols.
In the 1950’s experimental liver transplantation began to develop a surgical 
protocol and in 1963 Thomas Starzl carried out the first human liver transplant. 
Unfortunately the first patient, a 3 year old child with biliary atresia, died due 
to coagulopathy. Later that year, Starzl carried out a successful human liver 
transplant using treatments to overcome the coagulopathy and using a 
combination of corticosteroids, actinomycin C and azathioprine as 
immunosuppression (Starzl et al, 1968). During the 1970’s, liver 
transplantation activity plateaued out due to poor long term results and it was 
only with the introduction of veno-venous bypass and the advent of 
Cyclosporine A that liver transplantation expanded and became a recognised 
therapeutic modality for end stage liver disease in the 1980’s.
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The history of cardiac transplantation has received far wider publicity than any 
other organ the first successful human transplant being carried out by 
Christiaan Barnard in South Africa in 1967 (Barnard, 1967). The first attempt 
at human cardiac transplantation was carried out by James Hardy in Mississippi 
in 1964 using the heart of a chimpanzee and much of the work developing the 
technique of orthotopic cardiac transplantation was carried in out in dogs by 
Norman Schumway and Richard Lower in Stanford (Lower and Schumway, 
1960). Cardiac transplantation, however only became a widely recognised 
therapeutic modality in the 1980’s due to the poor results as a result of graft 
rejection prior to this.
In the wake of the success of these transplants, whole pancreas and lung 
transplantation have now become accepted methods of treating failure of these 
organs and are being carried out with improving results in specialist centres 
throughout the Western world.
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1:2 The development of modern immunosuppression protocols
The increasing success of organ transplantation over the last 30 years is due 
principally to the evolution of modem immunosuppressive drugs. In 1959 the 
antimitotic drug 6-mercaptopurine was shown to induce immunological 
tolerance in rabbits and subsequently its metabolite azathioprine was shown to 
be more effective and less toxic in dog renal allografts (Caine, 1960, Caine, 
Alexander and Murray, 1962) and this drug was then used effectively in clinical 
transplantation in 1963 (Murray et al, 1963). Corticosteroids were also known 
to have immunosuppressive properties and the combination of prednisolone 
and azathioprine became the “gold standard” for immunosuppression in the 
1970’s (Groth, 1972). Further progress in improving graft survival was made 
during this time by the use of lymphocytotoxic crossmatching and the matching 
of major histocompatibility antigens between the donor and recipient and by the 
use of antilymphocyte preparations. It was also noted around this time that 
deliberate pre transplant blood transfusion had a beneficial effect on graft 
survival (Opelz et al, 1973, Opelz et al, 1992).
The next major advance in transplantation immunosuppression was made in 
1976 by Jean Borel and his co-workers in the Sandoz laboratories in Basle, 
Switzerland with the discovery of the drug cyclosporin A (CsA) (Borel et al, 
1976). CsA works by inhibiting interleukin-2 synthesis and subsequently T-cell 
clonal expansion and was shown experimentally to prolong graft survival in
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animals (Kostakis et al, 1977, Caine and White, 1977) and subsequently in 
clinical transplantation (Caine and Wood, 1985, Caine, 1987). As a direct result 
of the introduction of cyclosporin A in the 1980’s, the one year survival of 
solid organ allografts has increased from around 60% in the 1970’s to 80-90% 
in the 1990’s with modem immunosuppressant regimes consisting of a 
combination of cyclosporin, azathioprine and prednisolone. CsA treatment 
does, however cause generalised immunosuppression and therefore patients are 
at increased risk of infection and malignancy. In addition, CsA has been found 
to be nephrotoxic in the longterm (Thomson, 1989).
Despite the advances made with the introduction of CsA, grafts are still lost at 
the rate of 5% per annum and new immunosuppressive agents are being 
developed to combat this. These include Tacrolimus (FK506), Sirolimus 
(Rapamycin), Mycophenylate Mofetil and Brequinar Sodium.
Tacrolimus is a macrolide antibiotic which acts, as does CsA, by inhibiting the 
transcription of the IL-2 gene. It does this by binding to the cytosolic 
immunophilin FK-BP which then inhibits the translocation of nuclear factor of 
activated T cell (NF-AT) and subsequently the transcription of IL-2. Studies of 
Tacrolimus in clinical organ transplantation have shown it to be at least as 
effective as CsA, however it does share the nephrotoxicity seen in CsA treated 
patients (Jain et al, 2000, Preston et al, 1998).
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Rapamycin (Sirolimus) acts by binding to the same cytosolic immunophilin as 
Tacrolimus (FK-BP), but acts by altering intracellular signalling in the T cell 
after IL-2 ligation. Clinical trials of rapamycin have suggested that it is a potent 
immunosuppressive agent which appears to act synergistically with CsA and 
possibly with Tacrolimus and so may allow a reduction in the dose of these 
drugs and therefore hopefully a reduction in the incidence of their side effects 
without loss of efficacy (Kahan, 2000, Latta, 2000, Khanna, 2000, Halloran, 
2000).
Mycophenylate mofetil (MMF) is a new immunosuppressant drug which has 
recently been introduced into clinical practice in this country. It acts by 
inhibiting DNA synthesis in T cells through blocking the activity of the enzyme 
inosine monophosphate dehydrogenase (IMPDH). MMF is mow being used 
widely both in primary immunosuppression protocols and as an alternative to 
azathioprine in sensitised patients(Carl et al, 1997, Seebacher et al, 1999, Puig 
et al, 1999).
Brequinar sodium is a drug initially developed as an anti-neoplastic agent which 
inhibits the activity of the enzyme dihydroorotate dehydrogenase (DHODH) 
and disrupts purine biosynthesis and therefore proliferation of activated cells 
(Makowka et al, 1993a and b). Although its effect in transplantation is likely to 
be due to its antiproliferative effect on alloreactive T cells it has been suggested 
that it may have more complex immunosuppressive effects including inhibition
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of IL-2 production (Forrest et al, 1994). Brequinar has not yet been accepted 
widely for clinical use but early experimental work suggests that it is a potent 
immunosuppressive agent (Kawamura et al, 1993).
1:3 The use of antibodies in clinical transplantation
Biological immunosuppression in the form of both polyclonal and monoclonal 
antibodies has been used clinically and experimentally in organ transplantation 
for many years. The success of these preparations has been at times 
disappointing, however as antibody production technology has improved and 
the preparations have become more refined, antibodies have become a useful 
adjunct to chemical immunosuppressants.
The use of polyclonal antibody preparations such as antilymphocyte serum 
(ALS) and antilymphocyte globulin (ALG) was pioneered by Starzl in the 
1960’s (Starzl, 1968). These preparations are raised by immunisation of horse, 
rabbits or goats with human lymphoid cells and act by depleting T and B 
lymphocytes from the circulation by opsonisation and by impairing the function 
of residual lymphocytes by modulating cell surface molecules (Powelson and 
Cosimi, 1994).
ALG was used during the 1970’s along with azathioprine and steroids but did 
not improve graft survival compared with azathioprine and steroids alone
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(Cosimi, 1976). ALG is currently used in some centres as induction therapy at 
the time of transplantation or in steroid resistant rejection as “rescue” therapy 
(Cosimi, 1988).
The production of monoclonal antibodies was first described by Kohler and 
Milstein in 1975 when they developed mouse tissue culture cell lines which 
produced anti sheep red blood cell antibodies (Kohler and Milstein, 1975). This 
hybridoma technology allowed the production of antibody preparations with 
consistent reactivity to particular antigens (Galfre et al, 1979). Monoclonal 
antibodies have been raised against many of the molecules involved in 
transplant rejection. Table 1.1 reviews the studies to date which have used 
monoclonal antibodies in a clinical setting. Despite the large number of 
monoclonal antibodies available, few have gained widespread acceptance as
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Monoclonal
antibody
Target
molecule
Type of graft Number of 
patients
Reference
OKT3 CD3 Kidney 123 Ortho Multicentre Tria 
Study Group, 1985 
Delmonico et al, 1988
BMA031 a/3  TCR Kidney 24 Knight et al, 1994
T10B9.1A-31 a/3  TCR Kidney 76 Waid et al 1992
Daclizumab CD25 Heart 55 Beniaminovitz, et a 
2000
Daclizumab CD25 Kidney 267 Ekberg et al, 2000
Daclizumab CD25 Kidney 116 Nashan et al, 1999
Daclizumab CD25 Islets 7 Shapiro et al, 2000
Basilximab CD25 Kidney 174 Kahan et al, 1999
BT563 CD25 Heart 60 Gelder et al, 1996
LO-Tac CD25 Liver 129 Reding et al, 1996
Odulimomab LFA1 Kidney 101 Hourmant et al, 1996
Enilomab ICAM1 Kidney 262 Salmela et al, 1999
BL-4 CD4 Kidney 12 Morel et al, 1990
MAX.16H5 CD4 Kidney 30 Reinke et al, 1995
OKT4A CD4 Kidney 30 Matas et al, 1995
Campath 1H CD52 Kidney 31 Caine et al, 2000
Table 1.1. Studies using monoclonal antibodies in clinical organ
transplantation
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effective immunosuppressants. Until recently, OKT3 was the only monoclonal 
antibody used widely in transplantation. This is a murine IgG2a monoclonal 
antibody directed against the CD3 molecule on the surface of T lymphocytes 
and it has been shown to be effective in reversing acute rejection by profound T 
cell depletion and modulation of the CD3/TCR complex (Cosimi et al, 1981, 
Masroor et al, 1994, Ortho Multicenter Transplant Study Group, 1985, 
Delmonico et al, 1988). The use of OKT3 has, however, been limited due to 
the attendant side effects of its use namely increased risk of infection and 
malignancy (Thistlethwaite et al, 1987, Monaco et al, 1987, Cosimi et al, 1987, 
Fung et al, 1987) and the cytokine release syndrome following the first dose 
(Chatenoud et al, 1990, Ambramowicz et al, 1989).
Monoclonal antibodies act in three ways. Firstly they can block a key cytokine 
or receptor ligand interaction in the immune system. One example of this is 
anti-CD25 mAb which blocks the interaction of IL-2 with its receptor. 
Secondly they can act by targeting and opsonising the target cell or molecule 
allowing recruitment of immune effector cells to destroy the cell. This 
mechanism appears to depend on adequate expression of the target molecule as 
well as the presence of the Fc region of the antibody. Campath 1H, an antibody 
directed against CD52, is a potent recruiter of effector cells and is thought to 
work in this way. Thirdly, monoclonal antibodies can achieve their cytotoxic 
effect by crosslinking target receptors and triggering apoptotic pathways by 
direct signalling mechanisms (Glennie and Johnson, 2000).
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The lack of success of monoclonal antibodies in clinical transplantation is partly 
due to the complexity of the response in humans and also to the fact that the 
antibodies used have been derived from animals. They have a short half life in 
the serum and are not universally effective in triggering human effector 
functions such as the complement system and Fc receptors. In addition, these 
mAbs can trigger the production of human anti mouse antibodies (HAMA) 
resulting in hypersensitivity reactions, reduced efficacy and enhanced clearing 
of the antibody from the serum (Schroff, 1985). In an attempt to overcome this 
problem, recombinant DNA technology has been used to produce rodent 
antibodies with varying degrees of humanisation (Riechmann et al, 1988). This 
has been achieved by either forming “chimeric” mAbs where the variable region 
of the rodent mAb is transplanted onto the constant region of the human 
antibody, or by producing “humanised” antibodies where the antigen binding 
loops, the so called complementarity determining regions (CDR), are derived 
from the rodent antibody and the rest of the mAb is human. Humanised 
antibodies are thought to be less immunogenic than chimeric antibodies while 
retaining the effector activity of the human antibody, however the humanisation 
process often results in a reduction of antibody affinity (Clark M, 2000). 
Examples of these engineered antibodies are CAMPATH-1, directed against 
human CD52 and used in lymphomas and autoimmune disease, and anti-IL-2R 
mAb (anti-Tac).
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Humanised monoclonal antibodies such as Daclizumab and Basiliximab have 
been shown to be effective as primary immunosuppression without the 
associated side effects of OKT3 in a variety of clinical transplant settings 
(Berard JL et al, 1999). Daclizumab, a genetically engineered humanised IgGl 
monoclonal antibody specific for the alpha chain of the IL-2 receptor, has been 
used in addition to primary immunosuppression in renal transplantation with a 
reduction in acute rejection episodes but without any increase in side effects or 
lymphoproliferative disorders at 1 year post transplant (Ekberg et al, 2000, 
Ekberg et al, 1999, Iverson et al, 2000, Nashan et al, 1997 and 1999). 
Daclizumab has also been used with encouraging results in cardiac 
transplantation, reducing the incidence of acute rejection episodes during the 
induction phase (Beniaminovtz et al, 2000). Attempts at using daclizumab 
instead of calcineurin inhibitors such as CsA and Tacrolimus have proved 
disappointing (Hirose et al, 2000). Perhaps one of the most important uses of 
daclizumab in clinical transplantation has been its use in successful human islet 
transplantation, allowing a steroid free regimen to be used (Shapiro et al, 
2000). Basiliximab is also a chimeric, humanised anti IL-2 receptor mAb and 
has been used in trials of renal transplantation with encouraging results (Kahan 
et al, 1999).
CAMPATH-1H is a humanised rat monoclonal antibody directed at the cell 
surface glycoprotein CD52, commonly called the CAMPATH-1 antigen. It
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effectively lyses human T and B lymphocytes, clearing them from the blood for 
up to a month after administration of the antibody. A recent study has shown 
that renal allografts can be maintained on low dose CsA alone after 
CAMPATH-1H treatment allowing a state of almost or “Prope” tolerance to 
exist (Caine R et al, 2 0 0 0 ).
The TCRa/p molecule has also been a target for monoclonal antibody 
intervention in clinical transplantation and is, in an experimental context, the 
subject of this thesis. BMA031 and T10B9.1A-31 are mouse anti-human oc/p 
TCR mAbs which have been used in clinical transplant studies. BMA031 has 
been tested in phase II and III clinical trials compared with OKT3 in renal 
transplantation with comparable efficacy (Knight et al, 1994, Dendorfer et al 
1990, Chatenoud et al, 1993). T10B9.1A-31 has been used in a phase II trial 
again compared to OKT3 and has been shown to be equally effective in 
reversing acute kidney graft rejection (Waid et al, 1992).
Monoclonal antibodies directed against the adhesion molecule LFA-1 have also 
been used in clinical studies. The antibody 25-3 was used in early studies in 
1995 to test tolerability and in a follow up study by the same group the 
antibody Oduli-momab directed against the alpha chain of LFA-1 was used in 
1 0 1  patients as induction therapy for kidney transplantation with comparable 
efficacy to rabbit ALG (Hourmant et al, 1996). The monoclonal antibody 
enilomab, directed against the adhesion molecule ICAM-1 has been tested in a
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trial of 262 recipients of cadaveric renal transplants. Enilomab was given along 
with standard immunosuppression and while the antibody appeared safe to use, 
there was no significant difference in acute rejection rates or graft survival in 
the antibody treated group compared with those patients receiving conventional 
immunosuppression alone (Salmela et al, 1999).
The CD4 molecule has been the subject of much experimental work in 
transplantation but few monoclonal antibodies directed at this molecule have 
been tested in clinical setting. OKT4A has been used in a study along with 
standard triple therapy to assess tolerability with some success (Matas et al, 
1995). Small studies have been carried out comparing the anti CD4 mAbs BL4 
and MAX.16H5 with ALG and OKT3 and ALG respectively. These studies 
showed that anti CD4 monoclonal antibodies have similar efficacy compared to 
the control groups (Morel et al, 1990, Reinke et al, 1995).
1:4 The immunological basis of transplantation
The graft acceptance induced by immunosuppressant drugs is due to non 
specific immunosuppression and this results in a variety of side effects, 
principally increased risk of malignancy and infection. Recipients of organ 
transplants are at increased risk of developing a wide range of malignancies 
mainly lymphomas, skin cancer (particularly in high risk regions) genitourinary 
malignancy, leukaemia, alimentary tract tumours and Kaposi’s sarcoma. The
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overall risk is approximately threefold (Sheil et al,1993). Infection due to viral, 
bacterial and fungal organisms are more common and are associated with up to 
85% of post transplant deaths (Drummer et al,1983, Ho et al 1983).
It is perhaps, then through a greater understanding of the immunology of the 
rejection process and how it can be manipulated that we will develop less toxic 
methods of inducing long term graft acceptance. The initial work into 
transplant immunology was carried out by Sir Peter Medawar who described 
the rejection of skin grafts in rabbits and noted that a second graft from the 
same donor was rejected more rapidly. This was termed the “second set” 
phenomenon and Medawar proposed that it was mediated by 
“immunocompetent cells” (Medawar, 1944). In 1954 Mitchison carried out 
adoptive transfer experiments on allogeneic tumour grafts in mice and 
demonstrated that lymphocytes can directly attack the graft. Also in 1954 
Billingham, Brent and Medawar transferred immunity to skin grafts in mice 
using lymphocytes (Billingham et al, 1956).
The importance of humoral factors in transplant rejection was also recognised 
and antibodies were chemically characterised in 1936 by Tiselius. The existence 
of heavy and light chains was described by Porter and Edelman in 1959 and the 
genetic background to the diversity of antibodies described by Tonegawa in 
1977. Kissmeyer-Nielsen documented the importance of antibody in the
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hyperacute rejection process in 1966 but the relative importance of antibody in 
acute graft rejection still remains controversial.
The identification of the specific transplantation antigens responsible for 
rejection began with George Snell in 1948 who coined the term 
“histocompatibility genes” and later that year Gorer identified the H2 locus in 
the mouse (Gorer et al, 1948). The MHC in man was first described in 1958 by 
Jean Dausset and was an essential step in developing tissue typing and the HLA 
system.
Much of the recent research in transplantation has been directed towards 
inducing tolerance to an organ allograft using a short pre or peri transplant 
course of treatment directed against specific molecules involved in the 
alloimmune response. The ultimate aim of such therapy is that the adaptive 
immune system of the recipient would be unresponsive to donor specific 
molecules without non specific immunosuppression.
l:4:lThe Major Histocompatibility Complex (MHC)
The MHC consists of a series of linked genes present, in man, on the short arm 
of chromosome 6 . This is the most highly polymorphic region of the genome 
and was first described in mice in 1948 (Gorer et al, 1948). These genes code
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for 3 classes of glycoprotein molecules called MHC class I, II and III. The first 
human MHC antigens were identified in 1958 by Dausset et al and the HLA A 
and B series documented in 1968. These discoveries were followed by the C 
series in 1970 and the class II antigens in 1973. In the mouse, the MHC is 
present on the mid portion of chromosome 17 and is called the H-2 complex 
and in the rat the MHC is present on chromosome 20 and called RT1 (Gunther 
et al, 1979, Gill et al, 1978, Klein J, 1979). In humans there are at least 17 class
I loci but the loci relevant to transplantation are HLA-A, -B and -C. The class
II region in humans is encoded by HLA-DR, -DP and DQ ( Trowsdale et al, 
1992,Campbell and Trowsdale, 1993), in the mouse by the H-2I region genes 
including I-A and I-E and in the rat by the RT1B and RT1D regions 
(Blankenhom et al, 1983, Blankenhom and Cramer, 1985).
Class I MHC is a heterodimeric membrane glycoprotein molecule consisting of 
a 45 kDa a  chain which is non covalently associated with the 12kDa P-2 
microglobulin. Its crystalline structure was discovered in the 1980’s by a 
combination of affinity chromatography to outline the amino acid sequence and 
x-ray crystallography to determine the 3 dimensional structure (Bjorkman et al, 
1987). The structure of the class I molecule is shown in figures 1.1a and b. The 
a  chain is a transmembrane polypeptide with 5 distinct domains. oci,a2 and (X3 
are extracellular with the a3 domain being membrane proximal and a4 and a5 
comprise the transmembrane and intracellular domains respectively. The P2- 
microglobulin is non covalently associated with the extracellular portion of the
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Figure 1.1a Schematic representation of the MHC class I molecule
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Figure 1.1b Structure of MHC Class I. The HLA-A2 
molecule depicted as a space filling model viewed from the 
side (a) and from above (b) as seen by the TCR. (from 
Garboczi et al, 1996). a l ,  a2  and a3  domains are shown in 
yellow and the |32m is in blue. Antigenic peptide is in red.
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a  chain. The a l  and al domains form an eight stranded (3-pleated sheet 
supporting two parallel strands of a-helix thus forming a peptide binding 
groove approximately 1x2.5 nm in size. The presence of peptide in the binding 
groove appears to be an essential part of the MHC complex since “empty” class 
I molecules are unstable and not expressed on the cell surface (Ljunggren et al, 
1990, Schumacher et al 1990). Class I MHC molecules bind to and present 
endogenously derived peptide sequences to cytotoxic T-cells usually as a result 
of viral infection of the cell. Newly synthesised class I a  chain associates with 
peptide in the endoplasmic reticulum, inducing a conformational change in the 
molecule and allowing binding of p2-microglobulin. The peptide-MHC class I 
complex is then transported to the plasma membrane via the Golgi apparatus 
and recognition by the CD8 + TCR takes place.
Class II MHC molecules are also transmembrane glycoproteins composed of 
31-34kDa a  and 26-29kDa p polypeptide chains, however both chains are 
transmembrane and consist of two extracellular domains each (Figures 1.2a and 
b). The peptide binding groove of the class II molecule is formed by the 
interaction of the a l  and pi domains but unlike class I, the ends of the binding 
cleft are open, allowing bound peptide to extend out from the cleft 
(Rammensee et al, 1993, Neeles and Ploegh, 1992). MHC class II molecules 
bind exogenously derived peptide ranging from 10 to 30 amino acids in length 
which has been endocytosed into the cell and degraded. The class II a  and P
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Figure 1.2a Schematic representation of the MHC class II molecule
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Figure 1.2b Structure of MHC Class II. The HLA-DR1 
molecule depicted as a space filling model viewed from the 
side (a) and from above (b). Domains 1 and 2 of the a  chain 
are shown in blue and domains 1 and 2 of the |3 chain in 
yellow. Antigenic peptide is in red (from Stern et al, 1994).
40
chains are synthesised in the ER where they associate with a third polypeptide 
called the invariant chain which is not encoded in the MHC. This association 
with the invariant chain is thought to be important for the transport of the class 
II heterodimer within the cell. This complex is then transported in the Golgi 
apparatus where the invariant chain cleaves, allowing peptide-MHC association 
in the endosomal compartment. The peptide-MHC II complex is then expressed 
on the plasma membrane where interaction with CD4+ TCR can take place. 
The class II region also encodes for proteins which deliver peptides for loading 
into class I MHC molecules. These are called Tap 1 and Tap 2 in humans, 
HAM 1 and HAM 2 in mice and mtp land mtp 2 in rats (Spies et al, 1992, 
Solheim et al, 1997, Monaco, 1993).
The class III region of the MHC encodes for components of the complement 
system and also includes the genes for heat shock proteins (HSP) and tumour 
necrosis factors a  and (3.
MHC class I and II molecules exhibit marked polymorphism. In the class I 
molecule this is mainly in the oti and a 2 domains with the (X3 domain highly 
conserved, presumably because of its association with p2-microglobulin. In the 
class II molecule the p chains exhibit a much greater degree of polymorphism 
than the a  chains, the majority of these polymorphic amino acids being grouped 
around the peptide binding groove. This suggests that each MHC allele only
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binds a specific spectrum of peptides thus making the interaction of the 
peptide-MHC complex with the TCR highly specific.
1:4:2 Factors affecting MHC expression.
MHC class I antigens can be expressed on all somatic cells however studies by 
Daar et al (1984) using a monoclonal antibody directed against the heavy chain 
of HLA-ABC antigens have shown that not all nucleated cells in the body 
constitutively express class I. Class I antigens were not detected on comeal 
endothelium, some intestinal glands, central nervous system neurones, the 
exocrine pancreas and acinar cells in the parotid. They were only weakly 
detected on several tissues including islets of Langerhans, the myocardium and 
hepatocytes. Class I antigens are however upregulated in several immune 
responses including transplant rejection. In contrast, expression of MHC class 
II antigens is limited mainly to cells of the immune system particularly dendritic 
cells, B lymphocytes, Langerhans cells of the epidermis, endothelial cells and 
activated T lymphocytes (Daar et al, 1984). Again, expression of class II is 
upregulated during immune responses, particularly graft rejection, and can be 
induced or increased by cytokines such as IFNy (Klareskog et al, 1986). Class 
II expression varies between species. Resting endothelial cells in rodents are 
class II negative and while in humans renal tubular cells show variable 
expression of class II, rat renal tubules are class II positive and mouse renal 
tubules class II MHC negative (Hart and Fabre, 1981, Fuggle et al, 1983, 
Benson et al, 1985).
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1:4:3 Minor Histocompatibility Antigens
Minor histocompatibility antigens (mH) were defined by Snell in studies in the 
mouse and are encoded by genes other than those of the MHC locus (Snell, 
1948). Minor antigens are less immunogenic than major antigens, but studies in 
mice have shown that skin grafts can be rapidly rejected in some MHC identical 
strain combinations (Loveland and Simpson, 1986). The existence of minor 
histocompatibility antigens in humans was suggested by skin graft rejection 
between HLA identical siblings and graft versus host disease in recipients of 
bone marrow grafts from HLA identical siblings. Minor antigens have also been 
implicated in chronic organ allograft rejection and may play an important role 
in graft rejection via the indirect pathway and in rejection of xenografts. It has 
been shown that minor antigens are peptides derived from endogenous proteins 
and are encoded by genes located on the mitochondrial genome, the Y 
chromosome and the autosomes (Simpson and Roopenian., 1997)
1:4:4 The T cell receptor
T cell receptors are molecules expressed by T lymphocytes which recognise 
processed antigen in the form of peptides bound to MHC molecules. This 
MHC restricted antigen recognition is mediated by the aP  T cell receptor 
which is expressed on over 95% of T cells in peripheral lymphoid organs, blood
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and lymph. A second type of T cell receptor, the y8  T cell receptor, is present 
on a small fraction of peripheral T cells which also mediates antigen 
recognition, but not in an MHC restricted fashion (Lawetzky et al, 1990).
Initial identification of the structure of the aP T cell receptor was by the use of 
clonotypic antibodies which outlined a heterodimeric disulphide bonded 
molecule with a molecular weight of approximately 90kDa (Figures 1.3a and 
b). The heterodimer consists of an a  (40-60 KD) and P chain (40-50 KD) each 
of which have two extracellular domains, one constant (C) and one variable 
(V). The junction between the V and C regions is encoded by a joining J 
segment gene and, in the case of the P chain, a diversity segment gene (D). The 
constant domain is attached to a transmembrane region by connecting peptides 
within which the interchain disulphide bond is formed. A short cytoplasmic tail 
is also present on both a  and P chains. The variable domains of the a  and p 
chains are formed into P pleated sheet structures and form the antigen binding 
site of the T cell receptor. Also present on all T cells is a series of polypeptides 
called CD3. This is tightly associated with the TCR and together they are 
referred to as the TCR-CD3 complex. Antibodies directed at the CD3 molecule 
can modulate T cell responses and are also able to co precipitate the TCR and 
CD3. CD3 comprises three polypeptide chains (each of 20-28 KD) on the 
surface of the T cell designated y, 8  and 8  which are closely related to a Q and, 
in rodents, a r\ chain. The y, 8  and e chains are structurally related members of
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Figure 1.3a Schematic representation of the ot/(3TCR/CD3 complex
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Figure 1.3b Structural basis of TCR interaction with MHC/peptide,
MHC Class I molecule in yellow and peptide antigen (red) associating 
with the V a  (purple) and V|3 (blue) chains of the TCR (from Garboczi 
et al, 1996)
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the immunoglobulin superfamily, whereas the C, chain is unrelated and forms £- 
C] dimers. The CD3 cytoplasmic domains each contain a motif called an Antigen 
Recognition Activation Motif or Tyrosine-based Activation Motif (TAM) 
(Weiss, 1991). CD3 is involved in signalling to the T cell after MHC/antigen- 
TCR interaction.
1:4:5 T cell development
T cells develop in the bone marrow from myeloblastic stem cells and then 
undergo maturation or “education” in the thymus. Briefly, thymic stromal cells 
present antigen to maturing thymocytes. Cells with high avidity for these self 
antigens are eliminated by apoptosis and cells which do not bind at all fail to 
proceed with maturation and die. Thus, highly autoreactive T cells and 
unreactive cells are eliminated by both positive and negative selection releasing 
only cells of medium avidity into the circulation. This process has made the 
thymus a potential target for immune modulation in transplant research and 
injection of donor antigen in the form of donor splenocytes and allogeneic 
peptide sequences has been carried out in animal models of graft rejection with 
variable success (Posselt et al, 1990, Walker et al, 1996).
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1:5 Cellular Interactions in Graft Rejection
Central to the process of graft rejection is the interaction between the host T 
lymphocytes and the antigen presenting cells (APC) of the graft. Host T cells 
can be functionally divided into helper and cytotoxic subsets. These T cells 
express the non polymorphic membrane glycoproteins CD4 and CD8  
respectively, correlating with the MHC restriction of each cell subset: CD4 +ve 
helper T cells are MHC class II restricted and CD8  +ve cytotoxic cells are 
MHC class I restricted. CD4 and CD8  were initially described simply as 
peripheral T cell markers, however it has been shown that they are receptors 
for MHC molecules and bind to structurally similar domains on their respective 
MHC molecules (Eichmann et al. 1987, Janeway, CA, 1989, Doyle and 
Strominger, 1987). Furthermore, their binding sites are distinct from the 
peptide binding domain allowing simultaneous binding of the TCR and CD4 or 
CD8  increasing the avidity of the interaction. Additionally, the cytoplasmic 
domains of CD4 and CD8  are associated with the intracellular protein kinase 
p56lck. This enzyme is essential for tyrosine kinase activation in response to 
TCR ligation, and so binding of CD4 and CD8  to the same MHC molecule as 
the TCR results in increased tyrosine phosphorylation and amplification of the 
signalling pathway in response to TCR-MHC ligation (Miceli et al, 1993). 
Alloantigen is presented in the form of peptide-MHC complexes by the 
interstitial dendritic cells (IDC) of the graft (also known as passenger 
leukocytes) (Roake et al, 1994). These cells are found in the parenchyma of all 
the commonly transplanted tissues (Hart et al, 1981, Daar et al, 1984), they are
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CD45 positive and constitutively express high levels of class I and class II 
MHC. These are specialised immunostimulatory cells and are central to the 
initiation of primary cellular immune responses both in the in vitro mixed 
lymphocyte reaction (Steinman et al, 1978, Mason et al, 1981) and in vivo 
(Larsen et al, 1990). Experiments by Lechler and Bachelor demonstrated the 
importance of these cells in transplantation by transplanting kidney grafts into 
recipient rats treated with enhancing antibody to allow graft acceptance. These 
grafts were then transplanted into a second recipient syngeneic with the first 
without rejection. They concluded that this was due to replacement of graft 
dendritic cells with recipient IDC since injection of the second recipient at the 
time of grafting with donor dendritic cells restored rejection (Lechler et al, 
1982). Various experimental strategies have been used to reduce the 
immunogenicity of organ allografts by depleting organs of IDC prior to 
transplantation (Goldberg et al, 1995, Brewer et al, 1989). Human vascular 
endothelial cells are also class II positive and can act as APC though not as 
efficiently as dendritic cells (Pober and Cotran, 1991, Hughes et al, 1990). 
Rodent resting endothelial cells are class II negative , however after in vitro 
culture with IFNy they are class II positive and capable of immune stimulation 
(Ferry et al, 1987).
The primary immune response to an allograft is initiated by direct stimulation of 
T cells by the allogeneic MHC antigens on graft APC’s. This direct T cell 
stimulation occurs because of the similarity between allogeneic and self MHC
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molecules and is unique in the immune system in two respects. Firstly, MHC 
molecules do not require processing prior to presentation (Auchincloss and 
Sultan, 1996) and secondly, the precursor frequency of T cells for a direct 
response is one hundred times that for a direct response to other environmental 
peptides (Sherman and Chattopadhyay, 1993). This phenomenon of 
alloreactivity has been explained by the high density of foreign peptide-MHC 
determinants on donor APC’s, allowing recipient TCR of lower affinity to 
respond (Bevan et al, 1984). Another explanation could be that a single allo- 
MHC product can stimulate multiple T cell clones by forming multiple “binary 
complexes” between MHC and different endogenous peptides (Matzinger et al, 
1977).
In addition to direct T cell stimulation, there is growing evidence that the 
presentation of processed donor MHC peptide by recipient APC also plays a 
role in allograft rejection. Although this is the natural physiological mechanism 
of antigen presentation, it has been referred to as the “indirect pathway” in 
transplantation (Auchincloss and Sultan, 1996) . Experiments by Professor 
Fabre’s group have shown that immunisation with donor peptide have resulted 
in accelerated graft rejection and an important role has been suggested for the 
indirect pathway in xenograft rejection (Benham et al, 1995, Fabre JW, 1996, 
Murphy et al, 1994, Dorling et al, 1996a and b).
50
The interaction between the TCR/CD3 complex and the MHC is essential for T 
cell stimulation, however it has been shown that full T cell activation requires 
co-stimulatory signals between T cell accessory molecules and their cognate 
APC surface proteins (Figure 1.4). The main APC-ligand receptor pairs 
thought to be involved in costimulation are CD40-CD40L, CD2-LFA3, CD28- 
B7 and ICAM1-LFA1. The TCR-MHC interaction provides signal one and the 
co-stimulatory molecules stimulate separate intracellular signalling pathways to 
provide the second signal for T cell activation. These co-stimulatory molecules 
are therefore potential targets for anti-rejection therapy and, as will be 
discussed later, experimental strategies using genetically manipulated animals 
and monoclonal antibodies against these molecules have been tried with 
variable success. Blockade of these co-stimulatory molecules may result in the 
T cell becoming anergic or unresponsive to further stimulation and this could 
be important in the induction of graft tolerance.
Following TCR/CD3 ligation, a signal is transduced from the T cell receptor 
complex to the nucleus of the cell to promote the transcription of genes 
important for T cell growth and differentiation. Antigenic engagement of the 
TCR/CD3 complex results in phosphorylation of the tyrosine or serine residues 
of the CD3 e, yand £ chains by p59^ and ZAP 70 which are closely associated 
with the TCR and p56lck. CD45 contributes to this by dephosphorylating 
tyrosine 505 of p56Ick. PhospholipaseC is then phosphorylated and a cascade of 
events is initiated. Phosphatidylinositol 4,5-biphosphate(PIP2) is hydrolysed to
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Figure 1.4 The molecular interactons involved in graft rejection
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form inositol 1 4,5 triphosphate(IP3) and diacylglycerol. This results in calcium 
ion mobilisation by IP3 and the binding of diacylglycerol to protein kinase 
C(PKC). Increased intracellular free calcium and sustained PKC activation 
promotes the activation of several nuclear regulatory proteins and gene 
transcription.
T helper cells, usually CD 4 T cells, regulate the cellular and humoral responses 
by secreting a variety of soluble mediators which bind to specific receptors on 
the target cell surface. These mediators are called cytokines and include the 
Interleukins (IL-2, IL-4 etc.), the Interferons (IFN) and the Tumour necrosis 
factors (TNF) (Dallman et al, 1992, Nadeau et al, 1996) (Figurel.5). Particular 
patterns of cytokine production by T helper cells have been identified (Mosman 
et al, 1986). T helper cells which produce IL-2, INF-y and TNFa are 
designated Thl cells and have been shown in experimental models to be 
responsible for cell mediated immune responses and may be the predominant 
cell type involved in graft rejection. Th2 cells, which produce IL-4, IL-5, IL-6, 
IL-10 and IL-13 and are responsible for humoral immune responses and 
polarisation towards a Th2 type response, may be associated with graft 
tolerance in some models. Some studies have, however, found that graft 
rejection is associated with a Th2 type response and in some models graft 
acceptance is associated with suppression of both the Thl and Th2 responses. 
The development of these cell types is itself regulated by cytokines. IL-12, a 
heterodimeric cytokine produced by monocytes, B cell, dendritic cells and NK
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Figure 1. 5 T helper cell differentiation and cytokine production
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cells, has been shown to be a key regulator of Thl/Th2 balance (Trinchieri, 
1993 and 1995). Once a naive CD4 cell is activated via the TCR it secretes IL- 
2 and expresses the IL-12 receptor. If it encounters IL-12 or CD8a+ dendritic 
cells then the IL-12Rp2 chain is upregulated and differentiation along a Thl 
pathway occurs. If, however, the activated Th cell encounters IL-4 and CD8a- 
dendritic cells the IL-12RJ32 is downregulated and differentiation along a Th2 
pathway occurs (Rengarajan et al, 2000).
1:6 The role of antibody in graft rejection
Hyperacute graft rejection as a result of preformed antibody to ABO blood 
group antigens and class I MHC (Baldwin et al, 1991) has been largely 
removed from clinical practice by the introduction of blood group matching and 
cytotoxic crossmatching prior to transplantation (Patel and Terasaki, 1969). 
Alloantibody dependant mechanisms have not been thought to be responsible 
for graft rejection, however it has been shown that in certain experimental 
circumstances alloantibody may effect graft rejection (Morton et al 1993). 
Alloantibody, principally IgG (Baldwin et al, 1991), may effect graft 
destruction either by antibody dependant cellular cytotoxicity (ADCC) or by 
complement mediated cell lysis.
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1:7 Chronic graft rejection
Chronic rejection (or chronic transplant dysfunction (CTD) is the irreversible 
loss of graft function which occurs late in the post transplant period. It affects 
over 35% of kidney grafts and is present in 70% of lung allografts and 50 % of 
heart transplants at 5 years (Kouwenhoven et al, 2000). The classical 
pathological feature is fibroproliferative endarteritis resulting in concentric 
myointimal proliferation affecting the small arteries giving the characteristic 
“onion skin” appearance. The precise cause of chronic graft rejection is unclear 
and experimental models are rare, however multiple immunological factors 
such as histocompatibility, acute rejection, sub optimal immunosuppression, 
non compliance and anti-donor antibodies have been implicated. Non 
immunological factors such as graft ischaemia, infection, hypertension, 
infection and hyperlipidaemia may also play a role (Azuma and Tilney, 1995, 
Kouwenhoven et al, 2000,).
1.8 Mechanisms of tolerance
The traditional definition of transplantation tolerance is “ specific absence of an 
immune response to an antigen”, however, recently the concept of “operational 
tolerance” defined as “the survival of a functional allograft in the absence of 
long-term exogenous immunosuppression even though the graft recipient may
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show apparent allorecognition of donor cells in vitro” has become more useful 
(Sachs, 1996).
Several strategies for the induction of tolerance to an allograft have been tried 
both experimentally and in clinical studies. The mechanisms responsible for 
tolerance induction can be divided into central (thymic) tolerance and 
peripheral tolerance. Central tolerance is due to clonal deletion of autoreactive 
T cells in the thymus (Burnet, 1959) and is responsible for tolerance to self 
antigens. The experimental evidence for this comes from work using TCR 
transgenic mice (Sha et al, 1988) whereby cells expressing a self reactive 
transgene were eliminated. TCR positive thymocytes are firstly subject to 
positive selection in the cortical region of the thymus where only T cells which 
interact with self MHC molecules survive. . Negative selection then occurs in the 
medullary region of the thymus where T cells expressing high affinity TCR for 
self antigen are eliminated by apoptosis. Thus autoreactive T cells are 
eliminated before they reach the periphery. Several investigators have 
attempted to induce tolerance to allografts by injection of donor antigen either 
in the form of donor cells or donor strain MHC peptide in an attempt to 
negatively select alloreactive T cells prior to transplantation (Posselt et al, 
1990, Odorico et al, 1992, Remuzzi et al, 1991, Campos et al, 1993, Walker et 
al, 1996).
Work using monoclonal antibodies against T cell surface molecules such as 
CD4, CTLA-4 and LFA-1 has suggested that neither the thymus nor clonal 
deletion are required for the induction of tolerance. It would appear that, in the
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transplant setting, extrathymic or peripheral mechanisms are more important 
for tolerance induction.
Several peripheral mechanisms have been proposed for the induction of 
tolerance (Figure 1.6). T cell ignorance occurs when antigen is presented in the 
context of MHC class I by non professional APC. The absence of 
costimulatory signals during T cell stimulation by either blocking co receptor 
interaction (in particular CD40-CD40 ligand and B7-1/2- CD28) or by antigen 
presentation by class II positive cells lacking co receptor (eg activated 
endothelial cells) can result in the inactivation of the T cell or the induction of 
anergy (Pleyer et al, 2000). Anergic T cells are unable to respond to further 
stimulation by normal APC. It has been suggested that lack of normal IL-2 
production and T cell proliferation caused by incomplete stimulation is the 
mechanism of anergy production (DeSilva et al, 1991). It has been suggested 
that such tolerance is “infectious” in that a cohort of tolerant cells are able to 
guide or regulate other T cells towards tolerance (Cobbold et al, 1996). This 
may occur by anergic T cells competing with immunocompetent cells at the site 
of antigen recognition for costimulatory molecules and cytokines ( the so called 
“civil service model”) (Cobbald et al. 1990, Waldmann and Cobbold, 1993). In 
1974 Gershon demonstrated that tolerance can be transferred by antigen 
specific T cells from tolerant animals (Gershon, 1975). He termed these cells 
suppressor cells and since then various hypotheses have been suggested to 
explain this observation. Most recently, suppressor or regulatory T cells have
58
Allospecific lymphocyte
Anergic I 
lymphocyte
Ignorance
Regulatory
lymphocyte Deletion
Immune
deviaton
Figure 1. 6 Mechanisms of transplant tolerance induction
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been found to be CD4 and CD25 +ve and a regulatory population of y/5 CD8 T 
cells have been detected (Powrie et al, 1993, Harrison et al, 1996).
As previously mentioned, T helper cells can be divided into Thl or Th2 
depending on their cytokine production. It has been proposed that tolerance 
induction may correlate with a deviation from a Thl to Th2 phenotype (Strom 
et al, 1996). An increase in IL-4 production has been seen in accepted heart 
grafts (Papp et al, 1992) and a reduction in IL-2 production has been noted in 
some models of tolerance (Dallman et al, 1991, Sayegh et al, 1995).
1.9 Monoclonal Antibodies in experimental transplantation
Monoclonal antibodies have proved useful reagents for various avenues of 
immunological research and their target specificity has allowed accurate 
definition of the cell types and molecular interactions involved in graft 
rejection. Monoclonal antibodies have also been used as therapeutic agents in 
both transplantation and autoimmune disease with variable results.
Cobbold et al described the use of monoclonal antibodies to deplete T cell 
subsets in thymectomised mice with resultant prolongation of skin graft 
survival(Nature 1984). Since then monoclonal antibodies have been raised to 
the major molecules involved in the rejection response in humans and rodents 
including CD4, CD8, CD45, MHC, CD3, CD28 TCR, LFA1, CD40, CD40L, 
ICAM1 and IL2 receptor( Table 1.2a-c).
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Monoclonal antibodies can be used in two ways to achieve graft tolerance. 
They can either deplete defined cell types or they can interfere with the function 
or interactions of various receptors. In humans depleting anti CD3 mAb’s have 
been used clinically for several years and depleting anti CD4, CD8 mAb’s have 
been used in rodent models to achieve graft acceptance (Cobbold et al, 1996). 
Non depleting anti CD4 monoclonal antibodies have also been used 
successfully in rodent models to induce transplant tolerance possibly by sparing 
regulatory populations of cells or by inducing anergy while retaining the ability 
to provide host defenses to infection etc (Darby et al, 1992, Binder et al, 2000). 
Cytotoxic T lymphocyte At immunoglobulin (CTLA4-Ig) in a similar way has 
been shown to block the interaction of B7 molecules with CD28 and CLTA4 
on T cells resulting in prolonged allograft survival in both rat and mouse 
models (Turka et al, 1992, Sayegh et al, 1995, Blazar et al, 1999). In an 
attempt to remove donor APC, depleting anti CD45 monoclonal antibody has 
been infused into human kidney grafts prior to transplantation with some 
reduction in acute rejection episodes, however as with other monoclonal 
antibodies used in clinical transplantation the results have been disappointing.
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Target
molecule
Monoclonal
antibody
Tolerogen Model Reference
CD3 FN18, B ll Skin Mouse Stevens et al, 1990
CD3 145-2C11 Islets Mouse Mackie et al, 1990
CD4 OKT4A Kidney Monkey Wee et al, 1992
CD4 OKT4A Skin Monkey Jonker et al, 1983
CD4 YTS-176.9.6 Heart Mouse Chen et al, 1992
CD4 YTS-191.1 Heart Mouse Pearson et al, 1993
CD4 0X38 Heart Rat Shizuru et al, 1990
CD4 0X35 Heart Rat llano et al, 1991
CD4 0X38 Heart/Kidney Rat Yin & Fatham, 1995
CD4 0X38 Islets Rat Seydel et al, 1991
CD4 0X35 Heart Rat Herbert&Rosser, 1988
CD4, CD8 0X38+0X8 Skin Mouse Cobbold et al, 1990
CD4, B7 0X38,
CTLA4Ig
Small bowel Rat Yin et al, 1996
CD4 KT6, YTS199 Heart Mouse Darby et al, 1992&94
Table 1.2(a). Monoclonal antibodies used in animal models of 
transplantation
62
Target
molecule
Monoclonal
antibody
Tolerogen Model Reference
TCR R73 Heart Rat Heidecke et al, 1993, 
95
TCR R73 Heart Rat Tsuchida et al, 1994
TCR R73 Kidney Rat Heidecke et al, 1996
TCR R73 Heart Rat Dufter et al, 1994
TCR R73 Heart Rat Knight et al, 1994
TCR R73 Heart Rat Van den Bogaerde et 
al, 1990
TCR H57-597 Bone
Marrow
Mouse Drobyski et al, 1996
CD28 CTLA4Ig Kidney Rat Sayegh et al, 1995
CD28 JJ319 Heart Rat Dengler et al, 1999
CD28, CD40 CTLA4Ig, anti- 
gp39
Skin/ heart Mouse Larsen et al, 1996
ICAM1, LFA1 Anti-ICAMl,
LFA1
Heart Mouse Isobe et al, 1992
Table 1.2(b). Monoclonal anti bodies used in animal models of
transplantation
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Target
molecule
Monoclonal
antibody
Tolerogen Model Reference
ICAM1, LFA1 Anti-ICAMl,
LFA1
Islets Mouse Arai et al, 1999
IL-2R NDS-61, 0X39 Kidney Rat Tellides et al, 1989
IL-2R ART-18, 0X39 Kidney Rat Udea et al, 1990
MHC-II HAK-75 Kidney Dog Yamamoto et al, 1984
MHC-II HAK-75 Heart Rat Sone et al, 1987
MHC-II BMAC4 Kidney Rat Priestley et al, 1992
TNFa,p Anti-TNFa,p Liver Rat Teramato et al, 1991
TNFa Anti-TNFa Heart Rat Imagawa et al, 1990
CD45RB MB23G2,
C363.16A
Islets Mouse Auersvald et al, 1997
CD25, CD54 NDS-61, 1A29 Liver Rat Gassel et al, 2000
CD2 RM2-2 Islets Mouse Kapur et al, 1996
IL-10 SXC.l Heart/Liver Mouse Li et al, 1998
CD40L Anti-CD40L Skin Mouse Markees et al, 1997
CD2, CD28 Anti-CD2,
CTLA4Ig
Hearts Mice Woodward et al, 1996
Table 1.2(c). Monoclonal antibodies used in animal models of 
transplantation
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1.10 R73 monoclonal antibody
In this thesis, the experiments centre on the use of an IgGi mouse monoclonal 
antibody to the rat ot/p T cell receptor. This mAb was developed and its 
properties described by Thomas Hunig in 1989. They found that R73 detects a 
pan T cell antigen expressed on 46% of splenocytes, 63% of lymph node cells 
and 3% of bone marrow cells. Using two colour flow cytometry, they showed 
that nearly all peripheral CD4+ve and 95% of CD8+ve lymphocytes react with 
R73. They also confirmed that it did not react with NK cells. Similar results 
were found in rat splenocytes. Soluble R73 was found to inhibit rat T cell 
activation in vitro but when the antibody is crosslinked in wells precoated with 
RaMIg antibodies there is marked stimulation with blast formation and IL2-R 
upregulation. R73 mAb was then used by the same group to characterise rat T 
cell subpopulations expressing ot/p and y/8 receptors (Lawetsky et al, 1990). 
They confirmed that peripheral T cells in the rat, as in humans and mice, can be 
divided into ot/p TCR+ve, CD5+ve and y/5 TCR+ve, CD5+ve and that these 
are phenotypically distinct from NK cells. Subsequently, Kinebuchi and 
colleagues have found that the determinant of this antibody exists on the 
constant domain of the rat TCR P chain (Kinebuchi et al, 1995). Initial 
investigators using R73 mAb in rats looked at its effect on experimental models 
of arthritis. They found that R73 suppressed established adjuvant arthritis and 
that this was associated with marked depletion of ot/p T cells in the periphery 
and in the synovium of treated animals(Yoshino et al, 1992). Marked CD5 +ve
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T cell depletion was also observed in these experiments suggesting that TCR 
modulation was not responsible for the effect on the disease process. Antibody 
production was not suppressed in this model.
The in vivo use of R73 monoclonal antibody was first described in a model of 
hamster to rat xenotransplantation. R73 was found to prolong graft survival in 
this model but no long term graft survival was achieved suggesting that 
concordant xenograft rejection is dependant on mechanisms other than T cell 
mediated graft destruction (Van Den Bogaerde et al, 1990).
Heidecke and colleagues observed indefinite graft survival in 20% of Lewis rats 
receiving a BN heart graft when a preoperative dose of 0.1 mg/kg R73 was 
administered (Heidecke et al, 1993). This was associated with T cell depletion 
in the grafts and some TCR modulation. Only slightly prolonged graft survival 
was obtained when the monoclonal antibody was administered post transplant 
and in combination with sub therapeutic doses of CyA. They concluded from 
this study that treatment with R73 prior to transplantation results in incomplete 
T cell activation and anergy. Long term heart graft acceptance has been 
reported in the DA to Lewis strain combination when recipient animals were 
treated with R73 from birth to 70 days post transplant (Dufter et al, 1994). 
This was associated with almost complete T cell depletion during the period of 
mAb administration with partial recover after cessation of treatment.
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A synergistic action of R73 with CyA was reported by Knight et al in 1994. In 
this study, a single dose of R73 administered along with CyA post transplant 
prolonged cardiac allograft survival in the Buffalo to Wistar Furth strain 
combination though indefinite graft survival was not obtained. Marked 
peripheral T cell depletion was again found with antibody detectable on 
circulating cells until day 7 after transplantation. They proposed that R73 may 
act by either altering T cell maturation either peripherally or in the thymus, by 
altering the function of mature peripheral lymphocytes or by TCR stimulation 
in the presence of a second signal inducing anergy. The synergism with CyA 
was thought to be the result of a reduction in the number of antigenic signals 
transduced via the TCR combined with CyA’s inhibition of the calcium- 
dependant activation pathway downstream.
Tsuchida et al published the first report of long term cardiac allograft 
unresponsiveness induced by a short pre transplant course of R73 in 
Transplantation in 1994. 50pg of R73 mAb was administered to Lewis rats 
days -2 and -1 relative to receiving a fully allogeneic BN cardiac allograft. All 
the grafts survived indefinitely and in addition second donor specific, but not 
third party, grafts were accepted. In vitro experiments showed transient CD4 
depletion and also TCR modulation suggesting that the mechanism of action in 
this model could be interference with antigen presentation by R73.
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R73 has also been found to abrogate accelerated rejection in rat cardiac 
allograft recipients (Heidecke et al, 1995) and this was associated with marked 
modulation of the a/J3TCR and reduced production of Thl cytokines IL-2 and 
IFNy and sparing of IL-4 as detected by immunocytochemistry.
These studies have suggested a potential role for R73 anti a / (3 TCR 
monoclonal antibody in the induction of long term graft unresponsiveness in 
rodent models of cardiac allografting. It appears from the results that the 
antibody must be administered pre transplant in order to obtain prolonged graft 
survival and that it may act synergistically with Cyclosporine A. The underlying 
mechanism of action of the antibody, however, remains unclear and 
mechanisms such as anergy, depletion of alloreactive T cells and polarisation 
towards a Th2 type response have been suggested.
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1.11 Aims and experimental design
It is hoped that the use of monoclonal antibodies to specific target molecules 
involved in the immune response to an organ allograft will allow tolerance to 
an organ allograft without the need for longterm immunosuppression and the 
associated side effects. The oc/(3 T cell receptor plays a central role in the 
molecular interactions in graft rejection and is therefore an ideal target for 
monoclonal antibody intervention. The main aim of this thesis was to study the 
ability of anti-a/pTCR therapy to promote allograft survival in a rat model of 
heterotopic cardiac transplantation.
The mouse anti-rat anti-a/(3TCR monoclonal antibody R73 was used in an 
attempt to induce longterm heart graft survival in a variety of rat strain 
combinations. Once the conditions for promotion of prolonged graft survival 
were established, experiments were carried to determine some of the 
mechanisms by which R73 mAb can induce indefinite graft survival. Initial 
experiments were carried out using flow cytometric analysis to quantify the 
effect of R73 on peripheral CD4 and CD8 T cells and determine whether cell 
depletion or receptor modulation play important roles in the induction of 
prolonged graft survival. Further studies were carried out using cell culture and 
RT-PCR to determine whether immune deviation of helper T cell subsets is a 
potential effect of R73 therapy. Finally, the potential role of apoptosis in this 
model was investigated by flow cytometric analysis of lymph node cells from 
R73 treated animals and by TUNEL staining of explanted heart grafts.
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It is hoped that the results from this thesis will provide a clearer understanding 
of the effects of monoclonal antibody therapy directed against the TCR and 
may give a clearer insight into how these affects can be obtained in human 
transplantation.
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CHAPTER TWO 
Materials and Methods
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2:1 Animals
2:1:1 Rats
Inbred adult male DA (RTla), Lewis (RT11), PVG (RT1C) and Brown Norway 
(RTln) rats were purchased from Harlan UK Ltd ( Bicester), and kept under 
humane conditions in compliance with Home Office regulations in the animal 
facility at the University Department of Surgery, Western Infirmary, Glasgow 
and the Central Research Facility in the University of Glasgow. All animals 
were maintained on standard rat diet and water and used when 8-16 weeks 
old.
2.1.2 Mice
Adult male Balb/c mice were purchased from Harlan UK Ltd ( Bicester) and 
used for antibody production by intraperitoneal injection of hybrid myeloma 
cells. They were housed in the University Department of Surgery animal facility 
as above and maintained on standard diet and water.
2:2 Surgical Procedures
2:2:1 Donor cardiectomy
Animals were placed in a sealed box and anaesthetised with halothane 
vapourised in oxygen. Animals were then shaved and maintained under 
anaesthesia using halothane administered via a nose cone. Cardiac
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transplantation was then carried out according to the technique described by 
Ono and Lindsey, 1969.
The peritoneal cavity of donor animals was entered using a long midline 
abdominal incision and the intestines reflected out of the abdomen and covered 
with a swab moistened in 0.9% saline. The inferior vena cava was then 
identified and the overlying peritoneum incised. 250 units of mucus heparin 
were then injected into the IVC. After a few minutes the animal was bled out 
by cutting the inferior vena cava and abdominal aorta. The chest was then 
rapidly opened by cutting the ribs along the mid axillary lines and reflecting the 
anterior chest wall cranially. The heart was then stopped and rapidly cooled by 
covering it with crushed ice or by administration of St Thomas' cardioplegia 
solution via the aortic arch. Once the heart had stopped beating the aortic arch 
and pulmonary trunk were dissected out with the aid of an operating 
microscope ( Wild Heerburg, Switzerland). The inferior vena cava and right 
superior vena cava were then dissected out, tied with a 5/0 silk tie and divided. 
A single 5/0 silk ligature was subsequently passed around the junction of the 
left superior vena cava and the azygous vein and both vessels divided. The 
ascending aorta was divided 2/3 of the way to the brachiocephalic trunk and 
the pulmonary trunk divided just proximal to its bifurcation. A single ligature 
was tied around the remaining vessels at the back of the heart and the excised 
and placed in a petri dish containing cold saline and kept in ice until 
transplantation. Cold ischaemic time did not exceed 30 minutes.
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2:2:2 Abdominal heart transplantation
The peritoneal cavity of recipient animals was entered through along midline 
abdominal incision and the intestines reflected out of the abdominal cavity and 
covered with a swab soaked in saline. The infra renal abdominal aorta and IVC 
were then dissected out and a suitable length chosen for anastomosis. 
Tributaries of the vein and lumbar vessels were then tied off and the vessels 
cross clamped proximally and distally. Occlusion clamps were then applied to 
the aorta and IVC of the recipient and the donor heart implanted by 
anastomosing the pulmonary artery then the ascending aorta end to side to the 
recipient IVC and abdominal aorta with a continuous 9/0 nylon suture(Ethicon 
Ltd, UK) under 16x magnification. The vascular clamps were then removed to 
re-vascularise the heart and the heart began to beat almost immediately. Any 
bleeding from the anastomoses was controlled with light pressure. Once the 
heart was beating in sinus rhythm the intestines were replaced in the abdomen 
and the wound closed using a continuous 3/0 catgut suture (Ethicon Ltd, UK). 
The animals were then allowed to recover in individual cages under a heat 
lamp.
2:2:2 Thymectomy
The thymus gland was removed from adult rats under halothane anaesthetia via 
a 2cm longitudinal incision in the neck and upper sternum and facilitated by a
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short sternal split ( Barbul et al, 1979). The strap muscles were split and the 
thymus mobilised with the aid of an operating microscope and removed with 
minimal bleeding. Due to the proximity of the thymus gland to the pleura of the 
lung, pneumothorax is a risk of thymectomy. This was avoided by the rapid 
closure of the neck wound after removal of the gland as the operator applied 
positive pressure ventilation by blowing through a syringe applied to the nose 
of the rat (Walker et al, 1994). This was carried out at least 2 months prior to 
heterotopic cardiac transplantation and subsequent analysis of peripheral blood 
lymphocytes by flow cytometry confirmed the depletion of Thy 1 positive 
lymphocytes (recent thymic emigrants).
2:3 Preparation of Cells 
2:3:1 Lymph node cells ( LNC)
Cervical and mesenteric lymph nodes were harvested from experimental adult 
male rats which were killed by cervical dislocation. Lymph nodes were stored 
in phosphate buffered saline containing 0.2% bovine serum albumin 
(PBS/BSA) and transferred to the laboratory in ice. The nodes were then cut 
with a scalpel and pressed through a stainless steel mesh to disrupt the node 
and allow removal of cells. Lymph node cells were then washed twice in 
PBS/BSA and resuspended in PBS/BSA and stored at 4°C until they were used
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in experimental procedures. Viability was consistently greater than 95% as 
determined by trypan blue exclusion.
2:3:2 Peripheral blood lymphocytes (PBL)
Adult male rats were bled out by direct cardiac puncture and the whole blood 
thoroughly mixed with lOu/ml heparin. The heparinised blood was then mixed 
in equal proportions with PBS and layered on percoll (9ml percoll ( Sigma 
Ltd)+1.3ml lOx HBSS+3ml water+130pl Hepes) and centrifuged at 400xg 
(2400 rpm) for 20 minutes at room temperature. Peripheral blood lymphocytes 
were then removed from the interface using a pipette and washed twice in PBS 
at 200xg for 5minutes after lysing the red blood cells (1ml water for 3 seconds 
followed by 1ml 2xNaCl). Cells were then resuspended in PBS/BSA and stored 
at 4°C until used in an experimental procedure.
2:3:3 Spleen cells
Spleens were removed from sacrificed rats and the capsule disrupted using 
forceps. Dead cells and debris were removed and the cells washed in 
PBS/BSA. Red cells were removed by hypotonic lysis and the splenocytes 
washed three times in PBS/BSA.
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2.4 Antibodies
A variety of antibodies were used in vitro to detect rat leukocyte populations: 
MRC 0X8 (CD8+ cytotoxic/suppressor T cells and the majority of NK 
cells(Gillman et al, 1982), W3/25 (CD4+ helper T cells and some macrophages 
(Brideau et al, 1980), EDI (macrophages, monocytes and dendritic cells), 
0X19 (pan T cell marker), 0X39 (IL-2Ra). All antibodies were obtained from 
Serotec, Oxford, UK.
2.4.1 R73 anti a/pTC R  mAb production
R73 hybridoma cells (European Collection of Animal Cell Cultures, Porton 
Down, Wiltshire, UK) were cultured and resuspended in PBS/BSA at 2xl05/ml 
and 0.5ml injected into the peritoneum of pristane (Sigma Chemical Company 
Ltd, Poole, UK) primed Balb/c mice. When an adequate volume of ascitic fluid 
had developed the mice were killed by cervical dislocation and the ascitic 
collected. The ascites was then centrifuged at 400xg (2400rpm) at 4°C for 20 
minutes and the supernatant removed and stored at -20°C. Antibody was then 
purified by Protein A affinity chromatography (Prosep-A, Bio-processing Ltd, 
England, UK). Antibodies were purified by adding an equal volume of diluting 
buffer (Glycine 75g/l, NaCl 17.6g/l, pH 8.6) for 12 h at 4°C, then centrifuging 
at 3000 rpm for 30 minutes at 4°C. A protein-A-sepharose column was 
prepared and equilibrated with binding buffer (Glycine 75 g/1, NaCl 8.8g/l, pH 
7.4), then loaded with diluted ascites. The IgG was eluted with 0.1M sodium
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citrate, pH 3.0, at a low rate of 2.7 ml/min into 4ml fractions and the Ig- 
containing fractions pooled and immediately dialysed with several changes of 
PBS to neutralise the pH. Purified antibodies were quantified by OD2go, and 
radial immunodiffusion (RID) using rat isotype specific RID plates and 
standards of known concentration (The Binding Site, Birmingham, UK).
2.4.2 rIL12 cytokine
Recombinant mouse IL-12 was a kind gift of Dr M Gately, Hoffman La Roche, 
Nutley, NJ.
2.4.3 In vivo administration of mAb
R73 mAb was administered to allograft recipient animals intraperitoneally at 
predefined doses and time points relative to transplantation in an attempt to 
prolong heart graft survival. Binding and activity was confirmed by flow 
cytometric analysis of peripheral blood lymphocytes lymph node cells from 
treated animals.
2.4.4 Monoclonal antibody conjugates used in flow cytometry studies
T cell populations in LNC and PBL prepared from experimental animals were 
identified by flow cytometric analysis. Detection was either by direct binding of 
fluorescein isothiocyanate (FITC) or phycoerytherin (PE) conjugated 
monoclonal antibodies to the relevant molecules or by detection of 
unconjugated mouse anti rat mAb by FITC conjugated rabbit F(abx)2 anti
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mouse Ig ( Dako Ltd, High Wycombe, UK)( RAM-FITC). Table 2.1 shows the 
antibody labeling protocol used in the flow cytometry studies.
Cell type Labeling antibodies
CD5 0X19 + RAM-FITC
CD4 R73-FITC + W3/25-PE
CD8 R73-FITC + OX8-PE
R73 mAb +ve RAM-FITC
R73 mAb saturation R73 + RAM-FITC
Table 2.1 Monoclonal antibodies used in flow cytometric analyses
2.4.5 Monoclonal antibodies used in immunohistological staining of 
cryostat sections
Cellular infiltration of cardiac allografts was analysed by immunocytochemistry. 
CD4 and CD8 T cell infiltration was detected by W3/25 and MRC 0X8 mAbs 
respectively. oc/f3TCR +ve cells were labeled with R73 mAb and CD5 +ve T 
cells detected with MRC 0X1 mAb. IL-2 receptor expression was detected by 
MRC 0X39 mAb and macrophages labeled with EDI mAb. Antibodies were 
purchased from Serotec Ltd, Oxford, UK.
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2.5 Flow cytometry
Depletion of CD5, CD4 and CD8 T cell populations in lymph nodes and 
peripheral blood of experimental animals was assessed by double labeling 
lymph node cells and peripheral blood lymphocytes with the relevant FITC and 
PE conjugates and analysed using a Coulter Epics XL flow cytometer (Coulter 
Ltd, Luton, UK). In addition R73 binding to T cells was analysed.
LNC and PBL were prepared as previously described. LNC were washed in 
PBS and resuspended in PBS/BSA at lx l06 cells per tube for analysis. PBL 
were washed twice in PBS by centrifuging at 200xg (1200rpm) for 5 minutes 
and resuspended in 1ml PBS/BSA and lOOpl per tube used for analysis.
Directly conjugated antibodies were added together and incubated at 4°C for 
45mins-l hour. 0X19 and R73 were added as first antibodies and incubated at 
4°C for 1 hour and then cells were washed twice in PBS/BSA at 200xg for 5 
minutes at 4°C. RAM-FITC was diluted 1:20 in normal rat serum and added to 
the washed cells and incubated at 4°C for 45minutes -lhour. Cells were then 
washed in 3ml PBS/0.2%BSA twice at 200xg for 5 minutes at 4°C and 
resuspended in 0.5ml PBS for analysis.
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Cell samples were then analysed using a Coulter Epics XL flow cytometer, live 
gates having previously been defined by forward and side scatter profiles using 
LNC and PBL from normal rats. 5-10000 events were counted per sample.
2.6 Immunocytochemistry
Heart grafts were excised from recipient animals at various time points, snap 
frozen in liquid nitrogen and stored at -70°C. 5\1 cryostat sections were then 
cut on to triple well glass slides and fixed in ethanol and immunoperoxidase 
staining carried out as follows. 5pl of diluted antibody (R73, W3/25, 0X8 and 
OX1 diluted 1:3 with PBS and EDI and 0X39 diluted 1:10 with PBS) was 
added (section 2.4.5) and incubated at room temperature for 45 minutes. Slides 
were washed three times in PBS and incubated with horseradish peroxidase 
conjugated rabbit anti mouse mAb (diluted 1:20 in PBS and normal rat serum) 
and developed using a DAB nickel substrate kit (Vector Ltd, UK). Slides were 
counterstained with haematoxylin, dehydrated in alcohol and a cover slip 
mounted and fixed with DPX. Cellular infiltrates were counted in stained 
sections over 10 high power fields (x40 magnification) using a cross line 
graticule on a Leitz Laborlux microscope.
2:7 Mixed lymphocyte culture
Unseparated lymphocytes at 2x105 were prepared from mesenteric and cervical 
lymph nodes of experimental animals as previously described. Splenocytes from
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naive Lewis and PVG third party rats were prepared as donor specific and third 
party stimulators by passing spleen cells through a fine steel mesh in tissue 
culture medium (RPMI/FCS; RPMI 1640 medium supplemented with 2mM L- 
glutamine, lOOU/ml penicillin, lOOpg.ml streptomycin (Life Technologies), 
50pM 2-mercaptoethanol (Sigma Ltd) and 5% heat inactivated FCS). 
Stimulator cells were washed twice and irradiated (20Gy) prior to use. 
Proliferation assays were set up in triplicate in 96 U-well plates (Life 
Technologies) using 2xl05 responders per well and 4xl05 stimulators per well. 
Plates were then incubated at 37°C in 5% C 02. After 3, 4 and 5 days culture, 
cells were pulsed with lpCi per well of [3H]- thymidine (Amersham 
International PLC, Little Chalfont, Bucks, UK) for 18 hours and harvested. 
Thymidine incorporation by proliferating cells was carried out using an 
automated cell harvester and liquid scintillation counter (1205 Betaplate, LKB 
Pharmacia, Milton Keynes, UK).
2:8 Cytokine bioassay for IL-2
The CTLL-2 lymphocyte line was maintained by 3x weekly treatment with 
human recombinant IL-2 (100 Unit/ml) and subculturing in RPMI 1640 
supplemented with 5% FCS, L-glutamine, penicillin/streptomycin and 2 
mercaptoethanol. Serial dilutions of supernatants from day 3 mixed lymphocyte
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culture of lymph node cells from R73 treated graft recipients and naive Lewis 
rats were mixed with 5xl03 CTLL-2 cells. Twenty four hours later, the cells 
were pulsed with 1 pCi/well titrated thymidine (Amersham International), 
incubated for 18 hours, harvested onto glass filter mats and counted in a liquid 
scintillation counter (1205 Betaplate, LKB Pharmacia, Milton Keynes, UK). 
Cytokine levels (in Units/ml) were calculated from a standard curve with rIL-2.
2:9 IFNy capture ELISA
96 well microtiter plates (Dynatech Immulon 4) were coated with lOOjLtl/ well 
of anti interferon gamma antibody (rabbit polyclonal anti-mouse IFNy, kind gift 
of Dr John Tite, Wellcome research laboratories, Beckenham, UK) at a dilution 
of 1:2000. After overnight incubation at 4°C, plates were washed three times in 
ELISA wash buffer (PBS containing 0.05% Tween 20) and blocked with 
200pl/well of PBS containing 10% FCS for 1 hour at 37°C. Plates were then 
washed three times in wash buffer and lOOpl/well of standard, control or 
sample (neat supernatant) added in triplicate and incubated at 37°C for three 
hours. After four further washes, the plates were incubated for 1 hour at room 
temperature with biotinylated ant-rat IFNy (DB1, kind gift of Dr P Vander 
Meide, Rijkswik, Netheriand). Plates were then washed six times and 100pl/ 
well of extravidin-peroxidase (Sigma Ltd) added and incubated for 1 hour at 
37°C. Plates were then washed a further eight times and lOOpl/well of 
tetramethyl benzidine (Dynatech Laboratories, Billinghurst, UK) added for 30
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minutes at room temperature and plates then read at 450nm using an ELISA 
plate reader (Dynatech MR 5000) and Biolinx software (Dynatech 
Laboratories).
2:10 Semiquantitative PCR to analyse cytokine mRNA in heart grafts
One hundred milligrams of frozen tissue from explanted heart grafts (snap 
frozen in liquid nitrogen) were homogenized in 1ml of TRIzol (Gibco BRL, 
Paisley, UK) and RNA prepared according to the manufacturers instructions. 
The purity and quantity of mRNA was determined by OD26o and OD26o/28o 
readings. For first strand cDNA synthesis, lOpg of total RNA were primed 
with lpg of oligo dT (Gibco BRL, Paisley, UK) and then mRNA was reverse 
transcribed in a 42pl reaction volume with 400U of Superscript RNase H 
reverse transcriptase (Gibco BRL) according to manufacturers instructions. For 
PCR, lpl of cDNA was amplified in a 25pi reaction volume containing 0.1 pi of 
Taq DNA polymerase, 0.4pl of lOmM dNTP mix, 2.5pi of 1 Ox reaction buffer 
(Boehringer Mannheim), 2.5pl of sense and antisense primers (0.2pm final 
concentration except p actin which was 0.1 pM), and sterile distilled water. A 
higher Mg Cl2 concentration was used when amplifying IL-4 message 
(2.5mM). Table 2.2 shows the oligonucleotide sequences used. PCR was 
performed using a Perkin Elmer Geneamp PCR system 9600 with an initial 
cycle of 94°C for 5 minutes, followed by multiple cycles of 94°C for 30 secs,
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45-65°C for 30 secs and 72°C for 30 secs with a final extension time of 5 
minutes. During the exponential phase of amplification, 10 tol5jfi aliquots of 
PCR product were sampled at 3 or 5 cycle intervals and analysed by 
electrophoresis in a 1.5% agarose gel and stained with ethidium bromide. 
Positive controls included RNA from Con-A stimulated rat lymphoblasts and in 
the case of IL-5, a rat IL-5 transfected cell line. As negative controls, primer 
and cDNA were omitted independently from the reaction mixture. All PCR 
products were of predicted size on electrophoresis and their identity verified by 
Southern blot analysis using digoxygenin-dUTP labeled (Boehringer 
Mannheim) specific internal oligonucleotide probes selected from published 
gene sequences. The integrity of RNA preparation and of the reverse 
transcription reaction was confirmed for each tissue by including a PCR 
reaction for (3 actin using three concentrations of cDNA ( neat, 1/10 and 
1.100), each amplified for 15, 20 and 25 cycles.
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Table 2.2 Olignucleotide sequences used in RT PCR detection of cytokine 
mRNA in explanted heart grafts
Cytokine Sense Antisense Internal Reference
IL-2 CAT GTA CAG 
CAT GCA GCT 
CGC ATC C
CCA CCA CAG 
TTG CTG GCT 
CAT CAT C
TTA CAG GTG 
CTC CTG AGA 
GG
McKnight et 
al, 1989
EL-4 TGA TGG GTC 
TCA GCC CCC 
ACC TTG C
CTT TCA GTG 
TTG TGA GCG 
TGG ACT C
GAC TCC ATG 
CAC CGA GAT 
GT
McKnight et 
al, 1991
IL-5 TTC TAA CTC 
TCA GCT GTG 
TCT GGG C
AAT GCC CAC 
TCT GTA CTC 
ATC ACG C
GCA ATG AGA 
CGA TGA GGC 
TT
Liberia et al, 
1991
EL-10 GTG AAG ACT
TTCTTTCAA
A
TGA TGA AGA 
TGT CAA ACT 
C
CTG AGG CGC 
TGT CAT CGA 
TT
Feng et al, 
1993
IL-13 CAG GGA GCT 
TAT CGA GGA 
GC
AAG TTG CTT 
GGA GTA ATT 
GAGC
TCC CTG TGC 
AAC AGC AGC 
AT
Lakkis et al, 
1993
IFNy ATG AGT GCT 
ACA CGC CGC 
GTC TTG G
GAG TTC ATT 
GAC AGC TTT 
GTG CTG G
AGC ATG GAT 
GCT ATG GAA 
GG
Dijkema et al, 
1985
IL-2Roc GTG GGG AGA 
TAA GGT GGA 
CGC AT
GAT CGA AAG 
GAG ACA GGC 
ACC C
TAT CAG GTA 
GCA GTG GCC 
AG
Page et al, 
1991
IL-2RP TAC TGG TCC 
TCG GCT GCT 
TCT TTG
GTG AAA GGC 
AGC AGA GGT 
GGG A
GAC CAT GCA 
GAT GCT CCT 
GT
Page et al, 
1991
P-actin ATG CCA TCC 
TGCGTC TGG 
ACC TGG C
AGC ATTTGC 
GGT GCA TGG 
AGG A
AGC AAG AGA 
GGT ATC CT
Nudel et al, 
1983
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2:11 Flow cytometric analysis of apoptotic cells
Lymph node cells were harvested from experimental animals and prepared as 
described earlier. The technique of propidium iodide (PI) staining of DNA to 
assess apoptosis has been described before (Nicoletti et al, 1991) and has been 
extensively used to quantify apoptosis in a heterogeneous cell population.
106 LNC were suspended in lOOpl PBS for analysis. PI staining solutions were 
prepared as follows. A stock solution of 2g sodium citrate, 121mg 
Tris,1044mg spermine tetrahydrochloride and 2ml Nonidet p40 was prepared 
in 2000ml deionised water and pH adjusted to 7.6. Trypsin was dissolved in 
stock solution and 450pl of this solution added to each tube containing LNC 
for 10 minutes at room temperature. 325pl of a solution of trypsin inhibitor and 
ribonuclease A was then added for a further 10 minutes at room temperature 
and finally 250pl of PI in stock solution was added to the samples for 10 
minutes in the absence of light.
Stained cells were then immediately analysed for PI fluorescence levels on the 
flow cytometer (20000 events per analysis) and apoptotic cells expressed as the 
percentage of cells in the sub diploid region of the cell cycle profile.
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2:12 In situ detection of apoptotic cells using TUNEL
Apoptosis was detected in situ using the Oncor ApoTag Peroxidase Plus In 
Situ apoptosis detection kit (S7101-Kit, Oncor Inc. Gaihtersburg, Maryland, 
USA). This technique is based on the terminal deoxynucleotidyl transferase 
mediated dUTP End Nick Labelling system whereby residues of digoxigenin- 
nucleotide are catalytically added to the 3' ends of the DNA fragments 
characteristic of cells undergoing apoptosis by the enzyme terminal 
deoxynucleotidyl transferase. This is then detected using a peroxidase detection 
system.
Cryostat sections of heart grafts were prepared as described above and fixed in 
10% buffered formalin. The sections were then post fixed in a 2:1 solution of 
ethanol and acetic acid and washed in PBS twice for 5 minutes and endogenous 
peroxidase quenched using 3% hydrogen peroxide for 5 minutes at room 
temperature. An equilibration buffer was then added followed by TdT solution 
which was then incubated for 1 hour at 37°C. The stop/wash buffer was then 
added followed by the anti digoxigenin peroxidase antibody for 30 minutes.
The diaminobenzidine (DAB) substrate solution was then added and the slides 
counterstained with methyl green. The slides were then dried in xylene and 
coverslips mounted using DPX.
Stained cells were counted at high power magnification (x40) over 10 high 
power fields per section or the whole section and results expressed as the mean
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and SD of at least 3 animals. Normal rat hearts were used as negative controls 
along with sections where distilled water was substituted for TdT solution and 
slides provided commercially with the detection kit used as positive controls.
2:13 Statistical analyses
Parametric data were analysed using the Student’s t test and non parametric 
data with the Mann Whitney U test where appropriate
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CHAPTER THREE
Prolongation of cardiac allograft survival in rats treated with 
R73 anti alpha/beta T cell receptor monoclonal antibody
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3.1 Introduction
The progress of organ transplantation is presently limited by the side effects of 
current immunosuppressive protocols. Much of the current research in 
transplantation is being directed towards the development of less toxic 
compounds which will reduce the need for immunosuppressive drugs such as 
corticosteroids, azathioprine, cyclosporin A and Tacrolimus. Ultimately, the 
ideal strategy is one which will result in long term graft acceptance without the 
need for continuous immunosuppression. One potential strategy is to target 
specific molecules involved in the immune response to an organ allograft using 
monoclonal antibodies. Monoclonal antibodies have been used in humans and 
experimentally in animal models against molecules present on donor APC such 
as CD45, LFA and B7 and molecules expressed by the T lymphocytes of the 
recipient CD3,CD28, CD2, CD4, CD8, CD40 ligand and IL-2R. However, the 
critical interaction between donor MHC-peptide and the T-cell receptor on 
recipient lymphocytes make these molecules ideal targets for monoclonal 
antibody therapy.
The direct interaction between intact MHC peptide complexes on donor APC 
and recipient T cells with the resultant cytokine production and clonal 
expansion of alloreactive T cells is seen as the principal step in the initiation of 
graft rejection. However, the possibility also exists that donor MHC and other 
polymorphic proteins in the graft can be processed and presented by recipient
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APC as foreign peptide bound to recipient MHC class II to recipient CD4+ T 
cells via the “indirect” pathway. There has been much evidence recently to 
support this theory in experimental models of both alio- and xeno­
transplantation and it is suggested that only a few antigenic determinants rather 
than the whole foreign protein are responsible for the T cell response (Dorling 
et al, 1996). The relative importance of the indirect pathway in the rejection of 
an allograft, however remains unclear.
I chose to investigate the ability of the monoclonal antibody R73 against the 
alpha/beta T cell receptor to prolong heterotopic cardiac allograft survival in a 
rat model. Heterotopic cardiac allografting in the rat is a well established model 
which is relevant to clinical organ transplantation since it involves the 
transplantation of a vascularised organ graft in a living biological system and 
while the transplanted heart does not contribute to the circulation of the animal, 
the cessation of a palpable heart beat in the abdomen is an easily detectable end 
point to indicate graft rejection. In addition, the immune system of the rat has 
been well defined and there are many reagents available for studies in this 
model. In this chapter, I investigated the ability of R73 monoclonal antibody to 
promote heart allograft survival in the rat model. R73 mAb is a mouse anti rat 
IgGi monoclonal antibody first described by Thomas Hunig in 1989. It is 
directed against the constant domain of the TCR ft chain (Kinebuchi et al, 
1995) and in soluble form this antibody inhibits T cell function in vivo and 
when immobilised in vitro, is a potent stimulator of T cell proliferation by
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promoting cross linking of the a/(3 TCR (Hunig et al, 1989). R73 mAb was 
raised and affinity purified as described in chapter 2. R73 was administered 
intraperitoneally to recipient animals and hearts monitored daily by palpation. 
The end point was taken as the cessation of a palpable heart beat in the 
abdomen of the recipient animal.
3:2 Ability of R73 mAb to prolong survival of Brown Norway heart grafts 
in Lewis recipients.
For these initial experiments the fully allogeneic BN[Brown Norway](RTln) to 
Lewis (RTl')strain combination was chosen. These rat strain combinations 
were selected because they differ from each other at both major and minor 
histocompatibility antigens and BN hearts are always rejected by Lewis 
recipients. Initially BN hearts were transplanted into the heterotopic abdominal 
site of 5 Lewis animals given only an isotype matched, irrelevant control mAb, 
0X21 which labels human C3b inhibitor. All hearts were rejected acutely with 
complete cessation of palpable cardiac contraction between 5 and 8 days after 
transplantation (median 8 days). To determine whether R73 mAb could 
prolong survival of BN hearts in Lewis recipients, affinity purified R73 mAb 
was administered to Lewis recipients at doses of either 25jig, 50pg and 200pg 
IP on days -2 and -1 relative to transplantation. This treatment regime was 
chosen because previous reports have shown that a similar regime induces 
indefinite heart graft survival (Heidecke et al, 1993; Tsuchida et al, 1994) and
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can abrogate accelerated kidney graft rejection in the same strain combination 
(Heidecke et al, 1995). As shown in figure 3.1, treatment of Lewis recipients 
with 50pg of R73 mAb resulted in significantly prolonged BN heart graft 
survival with a median survival time of 28 days (range 20-33 days, P= 0.02, 
Mann-Whitney test compared with control animals). Treatment with 200ug 
R73 mAb also resulted in significantly prolonged graft survival in this strain 
combination with a median graft survival of 21 days (range 17-32 days, P= 
0.008, Mann-Whitney test in comparison with the control group), however a 
dose of 25ug was insufficient to significantly prolong graft survival (P=l, 
Mann- Whitney test).
3:3 Strain dependant variation in heart graft survival following R73 mAb 
treatment.
In contrast to the previous reports, these R73 treatment regimes failed to 
induce indefinite BN heart graft survival in Lewis recipients and so in further 
studies we investigated whether R73 mAb treatment could induce long term 
allograft survival in other fully allogeneic strain combinations, namely 
DA(RTla) to PVG(RT1C) and Lewis(RTl1) to DA(RTla) strain combinations. 
For these studies 200jug R73 were administered to recipient PVG and DA 
animals on days -2 and-1 prior to transplantation as before and hearts 
monitored by palpation. As shown in figure 3.2, 80% of Lewis hearts survived 
for greater than 100 days in DA recipients after this treatment regime (median
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•  500ug 0X21 (n=5, MST 8 days)
°  25 ug R73 (n=4, MST 8 days)
O 200 ug R73(n=5, MST 21 days, P= 0.008*) 
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100
(U
>
ED(/)
CO
O)
80 -
60 -
40 -
20 -
days after transplant
Figure 3.1 Ability of R73 mAb to prolong survival of BN heart grafts 
in Lewis recipients. R73 mAb was administered to Lewis recipients 
of a BN heart graft on days -2 and -1 relative to transplantation. Graft 
survival was significantly prolonged in the groups receiving 50ug and 200ug 
on each day, though indefinite graft survival was not seen. Animals given 25ug 
R73 and OX21 control mAb rejected their grafts promptly within 10 days. 
*Mann-Whitney test compared with control group.
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Fig 3.2 Strain dependant variation in graft survival after R73 
mAb treatment. 200ug of R73 mAb was administered to PVG, Lewis 
and DA recipients of DA, BN and Lewis heart grafts respectively on 
days -2 and -1 prior to transplant. Prolonged graft survival was seen in 
the BN-Lewis strain combination but long term graft acceptance was 
only seen in the Lewis-DA low responder strain combination. Despite 
R73 treatment, PVG recipients promptly rejected DA donor hearts. 
*P=0.025, Mann-Whitney U test.
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100 days, range 11 to >100, P= 0.02, Mann- Whitney test) whereas median 
survival in the DA-PVG strain combination was only 10.5 days (range 10-11 
days). These experiments illustrate that the ability of R73 mAb to induce 
indefinite graft survival is highly strain dependant and although prolonged graft 
survival can be induced in the BN to Lewis combination, R73 mAb treatment, 
in our hands, only induces indefinite graft survival in DA recipients of Lewis 
hearts. In view of these results, the Lewis-DA strain combination was therefore 
used as the model in all further experiments.
3:4 Effect of different R73 doses on graft survival in the Lewis to DA 
strain combination
Having achieved indefinite graft survival in the fully allogeneic Lewis-DA strain 
combination using a 200pg dose of R73 mAb on days -2 and -1 prior to 
transplantation, we investigated whether altering the dose of R73 administered 
at these time points would influence heart allograft survival in this particular 
strain combination. DA recipient rats were given either 50pg, 200pg or 500pg 
R73 intraperitoneally on days -2 and -1 prior to receiving a Lewis heart graft 
and hearts again monitored by daily palpation. Figure 3.3 illustrates that 500|ng 
doses of R73 also induce graft survival of >100 days in the majority of treated 
animals (P= 0.03, Mann-Whitney U test) and although a dose of 50pg induces 
prolonged heart allograft survival, only 25% of grafted hearts survived longer 
than 100 days. These experiments demonstrate that as little as 50pg of R73
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Fig 3.3 Effect of different R73 doses on graft survival in the Lewis to 
DA strain combination. DA recipients of Lewis heart allografts were 
treated with either 50ug, 200ug or 500ug of R73 mAb days -2 and -1 prior 
to transplant. Control animals were given an irrelevant antibody (OX21) on 
the same days. Hearts were monitored daily by palpation and rejection taken 
as the cessation o f a palpable beat.The majority of animals receiving 200ug 
and 500ug doses o f R73 accepted their grafts indefinitely whereas only 
25% of those receiving 50ug mAb accepted their grafts for >100 days. 
*P=0.03, Mann- Whitney test.
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mAb administered on days -2 and -1 relative to heterotopic heart 
transplantation can prolong heart allograft survival in the Lewis to DA strain 
combination. Indefinite heart graft survival, however, was only induced by 
doses of 200pg and 500pg but there was no significant difference between 
these two treatment regimes. It was therefore decided to use 200|ig R73 mAb 
on day -2 and day -1 relative to heart transplantation for all further 
experiments.
3:5 The role of the thymus gland in R73 induced graft acceptance
The role of the thymus gland in self tolerance has been extensively investigated 
and based on these studies various strategies have been tried in rodent models 
to achieve tolerance to organ allografts by manipulation of the antigen 
presentation and T cell education in the thymus gland. These strategies have 
involved depletion of the peripheral T cell pool either by sub lethal irradiation 
or by administration of anti lymphocyte serum followed by the introduction of a 
permanent source of antigen either in the form of bone marrow transplantation 
along with the organ allograft (Odorico et al, 1992) or direct injection of 
allogeneic cells into the thymus itself prior to grafting (Posselt et al, 1990, 
Remuzzi et al, 1991, Campos et al, 1993) in the hope that potentially 
alloreactive cells in the thymus will be deleted. It has also been reported that 
tolerance induction by 0X38 anti CD4 mAb requires the presence of an intact 
thymus gland in the Lewis to DA strain combination (Jaques et al, 1998). We
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wished to investigate whether an intact thymus gland is necessary for long term 
graft survival induced by R73 mAb. We therefore carried out thymectomy in 8 
DA recipients at least 10 weeks prior to transplantation. The details of the 
surgical technique for thymectomy are outlined in chapter 2 (materials and 
methods). Recent thymic emigrants in the rat express the cell surface antigen 
Thy-1 for several days after emerging from the thymus and then become Thy-1 
negative (Mason and Williams, 1980). Complete thymectomy can therefore be 
confirmed by labelling Thy-1 with MRC 0X7. Experiments carried out in our 
laboratory using flow cytometric analysis of PBLs from animals thymectomised 
several weeks earlier have shown complete absence of Thy-1 lymphocytes 
confirming complete thymectomy in this model (results not shown). 
Thymectomised animals were then given 200pg R73 mAb on days -2 and -1 
prior to a Lewis heart allograft as before. The results shown in fig 3.4 illustrate 
that despite thymectomy R73 mAb induces indefinite graft survival in the 
majority of DA recipients and that this was not statistically significant 
compared to euthymic R73 treated DA controls (Mann-Whitney test). From 
these experiments it can be concluded that the presence of an intact thymus 
gland is not required for the induction of indefinite graft survival promoted by 
R73 mAb in this model.
3:6 Effect of IL 12 on graft survival after R73 mAb treatment
CD4 +ve T cells play a critical role in allograft rejection and recent evidence 
has shown that the CD4 population can be divided in to two distinct subsets i.e.
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Fig 3.4 R73 induced graft acceptance does not depend on 
the presence of an intact thymus gland. DA rats underwent 
thymectomy at least one month prior to R73 treatment and 
Lewis heart grafting. Over 80% of rats accepted their grafts 
indefinitely suggesting that R73 does not achieve indefinite 
graft survival by acting on the thymus
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Thl and Th2 cells as defined by their cytokine repertoire. As discussed earlier, 
Thl cells are broadly thought to be responsible for allograft rejection and Th2 
cells for graft tolerance. IL-12 is a heterodimeric cytokine produced by 
phagocytic cells and B cells with a variety of effects in particular the 
upregulation of IFNy production, enhancement of cytotoxic T cell and NK cell 
activity and promotion of Thl responses (Trinchieri and Scott, 1994).
We investigated whether graft rejection could be induced in DA rats treated 
with R73 mAb by administering lpg rIL12 (Kind gift of Dr M. Gately, 
Hoffman-LaRoche) to DA rats intra peritoneally on days 0-4 after receiving a 
Lewis heart allograft (day 0 being the day of transplantation). R73 mAb was 
administered as before to all recipient animals prior to grafting. Fig 3.5 shows 
that administration of IL12 abrogated graft survival in the majority of treated 
recipients with only 25% of grafts surviving greater than 100 days. This 
contrasts sharply with animals given R73 alone who would be expected to 
accept their grafts in 80% of cases.
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Fig 3.5 Effect of IL-12 on graft survival after R73 mAb 
treatm ent.lug of rIL-12 was administered to R73 treated 
recipient DA rats on days 0-4 relative to receiving a Lewis heart 
allograft. IL1-2 abrogated the indefinite graft survival induced by 
R73 in the majority of the R73 treated recipients.
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3:7 Discussion
The goal of transplant research is the induction of long term allograft 
acceptance by the administration of a short course of specific therapeutic 
immunosuppression which does not result in long term impaired immune 
responses. The ot/p TCR is an attractive target for immune modulation by 
virtue of its critical interaction with the MHC on donor cells and therefore the 
aim of the experiments reported in this chapter was to find out whether R73 
anti-TCR mAb therapy could prolong cardiac allograft survival in a rat model 
and if so what factors influenced the in vivo effect of this monoclonal antibody. 
The results in this chapter show that a short preoperative treatment with R73 
mAb can induce prolonged allograft survival in certain rat strain combinations. 
Only in the Lewis to DA combination, however, could indefinite graft survival 
be achieved using R73 mAb. Prolonged graft survival was seen in the BN to 
Lewis strain combination however no grafts survived longer than 35 days. This 
finding is consistent with previous reports (Heidecke et al, 1995). Tsuchida and 
colleges however, reported tolerance to rat heart allografts in this strain 
combination using a dose of only 50pg R73 (Tsuchida et al, 1994). In the DA- 
PVG strain combination R73 did not significantly prolong graft survival over 
untreated controls.
This strain dependant variation in response to immunomodulatory treatments 
has been seen in other rodent models of allograft rejection (McConnel and Hall,
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1989; llano et al, 1989 and 1991, Walker et al, 1996). The Lewis-DA 
combination is regarded as a low responder strain and appears more susceptible 
to immunosuppressive protocols designed to induce transplant tolerance. 
Despite this, unmodified DA recipients acutely reject Lewis heart allografts 
within 10 days suggesting that the strain variation reflects a susceptibility to 
immune modulation rather than a weak rejection response. Prolonged, post 
transplant R73 mAb treatment was not used in any of the above experiments 
and it is interesting to note that increasing the dose of R73 mAb to 500jxg did 
not improve long term graft survival over the 200pg dose in the Lewis to DA 
strain combination. This is probably due to either saturation of R73 binding 
sites to the a/p  TCR in vivo at and above a dose of 200|ig or the neutralisation 
of the xenogeneic mouse mAb by an anti mouse Ig response in the recipient rat. 
This problem has been highlighted in human transplantation using xenogeneic 
antibodies where repeated use of the antibody is ineffective due to such a 
response. Attempts have been made to overcome this by the construction of 
chimeric monoclonal antibodies in which the constant region of the Ig molecule 
is substituted with human amino acid residues. Heidecke and colleagues have 
observed that pre operative rather than post operative administration of R73 is 
essential for long term graft acceptance though this theory was not tested here 
(Heidecke et al, 1995).
The a/p  TCR is present on the majority of peripheral T cells and those found in 
the thymus gland (Lawetzky et al., 1990). It is possible therefore that R73 acts
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by either entering the thymus and modulating T cells centrally or depleting 
peripheral T cells allowing a prolonged source of alloantigen to modify T cells 
in the thymus resulting in central tolerance to the allograft. Removing the 
thymus gland prior to transplantation would abrogate graft tolerance in this 
model were this the case. In this model, however, thymectomy prior to 
transplantation had no effect on graft acceptance with over 80% of 
thymectomised DA rats accepting their Lewis heart allografts indefinitely after 
R73 treatment. It would therefore appear that R73 acts on the peripheral T cell 
pool to induce graft acceptance in this model and does not depend on a 
constant supply of immunomodulated thymic emigrants. These results contrast 
sharply with those reported for anti-CD4 induced transplant tolerance in the 
rat. Thymectomy carried out greater than 40 days prior to transplant under 
cover of anti-CD4 mAb abrogates tolerance in this model possibly due to the 
lack of immunoregulatory recent thymic emigrants which would otherwise have 
a suppressive effect on mature peripheral CD4 positive T cells, thereby 
preventing them from mediating graft rejection (Herbert and Roser, 1988, 
Jaques et al, 1998).
Interestingly, permanent graft survival after R73 mAb treatment in the Lewis- 
DA strain combination is abrogated in the majority of recipients by post 
transplant administration of the proinflammatory cytokine IL-12. Interleukin-12 
has been shown to promote the development of CD4 +ve T cells with a Thl 
phenotype and administration of EL-12 in vivo accelerates auto immune
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diabetes in NOD mice (Trinchieri, 1994, Trembleau et al, 1995). Rejection of 
cardiac allografts in R73 treated recipients animals could result from the 
augmentation of cytotoxic T cell or NK cell activity in the graft induced by 
exogenous IL-12. IL-12 may also promote CD4 +ve Thl cell development, a 
form of immune polarisation which has been shown to be associated with graft 
rejection in some experimental models (Takeuchi et al, 1992; Dallman et al, 
1991). This observation would therefore support the hypothesis that R73 acts 
by altering the peripheral T cell response to a heart allograft and suggests that 
although T cells present in recipient animals after R73 therapy are unresponsive 
to alloantigen they are still responsive to exogenous cytokine.
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3:8 Summary
3:2 Administration of two preoperative doses of anti-a/p TCR mAb (R73) 
significantly prolongs the survival of BN cardiac allografts in Lewis recipients 
but only when 50|ig (P= 0.02) or 200pg (P= 0.008) of R73 are given at each 
time point. Permanent graft survival is not obtained in this strain combination.
3:3 Administration of 200(j,g R73 mAb prior to transplantation results in 
indefinite (>100days) graft survival in the Lewis to DA strain combination but 
does not significantly prolong graft survival in the PVG recipients of a DA 
heart allograft.
3:4 200p,g and 500pg of R73 mAb given on days -2 and -1 are equally 
effective in promoting permanent graft survival in the Lewis to DA strain 
combination. A 50pg dose of R73 at these time points prolongs graft survival 
but not permanently.
3:5 The ability of R73 mAb to prolong graft survival in the Lewis to DA strain 
combination is not dependant on the presence of an intact thymus gland.
3:6 The effect of R73 mAb could be reversed by the administration of the 
proinflammatory cytokine IL-12.
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CHAPTER FOUR
In vivo effects of R73 monoclonal antibody therapy on a/p TCR
positive cells
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4.1 Introduction
The results described in the previous chapter show that a short pre operative 
course of 200pg R73 anti oc/(3 TCR mAb induces permanent survival of a 
Lewis heart allograft in DA recipient animals. The factors responsible for 
overcoming the rejection response to an allograft remain unclear despite 
intensive investigation by many groups. It is clear, however, that multiple 
effector mechanisms are involved and these can broadly be divided into central 
and peripheral mechanisms. Central tolerance, where alloreactive T cells are 
eliminated in the thymus gland, or where T cells become tolerised to 
alloantigen in the thymus has been suggested as a mechanism in some 
experimental models of transplantation (Posselt et al, 1990, Sayegh et al, 
1993). Several mechanisms have also been suggested whereby monoclonal 
antibodies can induce permanent graft acceptance by their effects on the 
peripheral T cell pool. Firstly, they may cause deletion of alloreactive T cells 
either by clonal elimination or they may stimulate activation induced cell death 
in activated T lymphocytes. Secondly, anergy may be induced whereby T cells 
are rendered unresponsive to antigenic challenge by altered signalling events at 
the time of antigen recognition. This can be induced either by interruption of 
costimulatory signals, in particular the B7-CD28 pathway where CTLA4 Ig 
construct has been used experimentally with some success (Sayegh et al, 1995). 
It has been suggested that this partial signalling may act by altering the 
amplitude of TCR induced signals. Thirdly, long term allograft survival may be
110
induced by peripheral CD4 T cell mediated suppression. The concept of T cell 
suppression has been supported by adoptive transfer experiments in models of 
transplantation using non depleting anti CD4 mAb’s and has been termed 
infectious tolerance (Waldmann and Cobbald, 1993).
As shown in the last chapter, the ability of DA rats to accept a fully allogeneic 
Lewis heart graft after R73 treatment does not depend on the presence of an 
intact thymus gland suggesting that in our model R73 does not act directly on 
the thymus gland or require the presence of recent thymic emigrants. R73 
therefore would appear to act by disabling the peripheral T cell pool. This is in 
contrast to some reports using anti-CD4 mAb therapy in rodents which has 
shown that thymectomy abrogates tolerance induction suggesting a role for 
recent thymic emigrants in the maintenance of graft tolerance in certain models 
(Jaques et al, 1998, Herbert and Rosser, 1988).
In the experiments described in this chapter we sought to identify possible 
peripheral mechanisms of R73 induced heart allograft acceptance in the Lewis- 
DA rat strain combination by investigating the in vivo effects of R73 on 
peripheral T cell subsets and their cell surface antigens. CD4 and CD8 T cells 
express the a/p  TCR and the interaction of the T cell receptor on these cells 
with allogeneic MHC on donor APC has been shown to be critical for 
allorecognition and rejection of an organ allograft. Depletion of CD4 and CD8 
T cells has previously been shown in some experimental models to be 
responsible for abrogation of the rejection response (Cobbold et al, 1984). In 
the following experiments CD4 and CD8 T cell depletion after R73 mAb
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therapy was examined using flow cytometric analysis of lymph node cells and 
peripheral blood lymphocytes. In addition, modulation of the a/p  T cell 
receptor on the surface of T cells was examined by flow cytometry. In separate 
experiments, DA recipients of Lewis heart grafts were killed 7 days after 
transplantation and the heart grafts subjected to immunohistochemical analysis 
to determine the degree of cellular infiltration in rejecting and non rejecting 
grafts.
4.2 Flow cytometric analysis of T cell subsets after R73 therapy
Lymph node cells (LNC) and peripheral blood lymphocytes (PBL) were 
harvested from R73 treated allograft recipients sacrificed on days 4, 7, 21 and 
100 after transplantation. Normal DA lymphocytes were used as controls. The 
cells were isolated and prepared as described in chapter 2 (materials and 
methods) and subjected to two colour flow cytometric analysis. The FITC and 
PE conjugated antibodies used in this analysis are illustrated in table 4.1.
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T Cell Subset FITC/ PE conjugate
CD4 R73-FITC + W3/25-PE
CD8 R73-FITC + OX8-PE
CD5 0X19 + Rabbit anti mouse-FITC
Table 4.1. Cell labelling protocol for flow cytometric analysis of LNC and 
PEL. 8jil of undiluted antibody conjugate was added to 2.5x10s- lxlO6 cells 
per tube for analysis. Rabbit anti mouse-FITC was diluted 1:20 with PBS and 
rat serum as a blocking agent.
Cells coated with R73 mAb were detected by adding rabbit anti mouse-FITC 
conjugate and saturation of TCR with R73 detected by incubating cells with 
saturating dose of R73 (8pl undiluted) and then rabbit anti mouse-FITC. Data 
are expressed as the mean and standard deviation of 3 or 4 animals in each 
group except at the day 21 time point where two treated animals were 
analysed. Paired comparisons were made between the treated groups and 
normal controls using the student’s t test as were comparisons between LNC 
and PBL groups at each time point. Significance was taken at the 5% level in 
all cases.
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4:2:1 T cell depletion in lymph nodes and peripheral blood of R73 treated 
graft recipients.
As shown in figure 4.1 and figure 4.4, the percentage of lymph node cells 
expressing the pan T cell marker CD5 as detected by MRC 0X19 mAb was 
significantly reduced at days 4 (mean 25.5%, SD 2.9, P= 0.0001), and 7 (mean 
28.8%, SD 2.1, P= 0.0009) in animals receiving 200pg R73 days -2 and -1 
prior to a Lewis heart allograft compared with lymph node cells harvested from 
normal DA rats (mean 78.3%, SD 5.7). By days 21 (mean 67.2%, SD 5.4) and 
100 (mean 72.6%, SD 7.4) after transplantation total T cell numbers had 
recovered in R73 mAb treated animals and although T cell recovery appears 
incomplete even at these late time points, the difference is not statistically 
significant.
T cell depletion in the peripheral blood of treated animals was again profound 
(figure 4.1b and figure 4.5). CD5 positive T cells were significantly depleted at 
day 4 (mean 0.3%, SD 0.4, P= 0.0009) and day 7 (mean 15%, SD 1.4, P= 
0.008) compared to untreated control animals (mean 63.9%, SD 9.4). 
Recovery of T cells expressing this marker was again seen at 21 days (mean 
63.4%, SD 18.0) and 100 days (mean 61.5%, SD 5.6) after Lewis heart 
grafting. Once again, although T cell recovery appears incomplete at days 21 
and 100 after grafting, there was no significant difference compared to 
untreated animals.
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Figure 4.1. CD5 positive T cell depletion in DA recipients of a Lewis 
cardiac allografts.. Lymph node cells (LNC) and peripheral blood 
lymphocytes (PBL) were harvested on days 4, 7, 21, and 100 relative to 
transplantation from recipient animals treated with R73 mAb 200ug days 
-2,-1 prior to transplant and from normal DA control animals. Cells were 
labelled with MRC OX19 (CD5) mAb and then rabbit anti mouse FITC 
conjugate and analysed by flow cytometry. * Student’s t test.
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It is also notable that R73 mAb treatment depletes T cells significantly more 
effectively in peripheral blood than in the lymph nodes at both day 4 
(P=0.0001) and day 7 ( P= 0.01) post transplant.
4:2:2 CD4 T cell depletion in lymph nodes and peripheral blood after R73 
mAb treatment.
Depletion of CD4 T cells in the lymph nodes harvested from R73 treated graft 
recipients mirrored that found for cells expressing CD5 (figures 4.2 and 4.4). 
Percentage of CD4 T cells was lowest at day 4 (mean 13.4%, SD 4.7, P= 
0.003)) and day 7 (mean 22.4%, SD 5.9, P= 0.02) compared to normal DA 
animals (mean 62.8%, SD 6.3). Recovery was almost complete by day 21 
(mean 57.2%, SD 12.9)and day 100 (mean 44%, SD3.7).
Depletion was again more pronounced in the peripheral blood of R73 treated 
animals (figure 4.2b and figure 4.5) with mean percentage of CD4 T cells 0.1% 
(SD 0.1, P= 0.001) at day 4 and 7.6% (SD 5.1, P= 0.01) at day 7 compared to 
53.8% (SD 9.1) in control animals. Recovery of cell numbers was again 
complete by day 21 (mean 44.5, SD20.4).
4:2:3 CD 8 T cell depletion in lymph nodes and peripheral blood after 
R73 mAb treatment.
As shown in figures 4.3 and 4.4, CD8 T cells were depleted to 2.5% (SD 0.8, 
P= 0.001) in the lymph nodes and zero in peripheral blood (figure 4.5) of R73
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Figure 4.2. CD4 T cell depletion in DA recipients of a Lewis heart 
allograft.. Lymph node cells (LNC) and peripheral blood lymphocytes 
(PBL) were harvested on days 4, 7, 21, and 100 post transplant from 
recipient animals treated with R73 mAb 200ug days -2, -1 prior to 
transplant. The cells were then double labelled with R73 Fite and W3/25 PE 
conjugates and analysed by flow cytometry. * Student’s t test.
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Figure 4.3. CD8 T cell depletion in DA recipients of a Lewis heart 
allografts. Lymph node cells (LNC) and peripheral blood lymphocytes (PBL) 
were harvested on days 4, 7, 21, and 100 post transplant from recipient animals 
treated with R73 mAb 200ug days -2, -1 prior to transplant. The cells were then 
double labelled with R73 Fite and 0X 8 PE conjugates and analysed by 
flow cytometry. * Student’s t test.
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Figure 4.4 Flow cytometric analysis showing CD5,CD4 and CD8 T cell 
depletion in the lymph nodes of DA graft recipients after R73 mAb 
treatement at days 4 and 7 after grafting. Two colour fluorescence analysis 
using FITC onjugated R73 on Y axis (log10 FITC signal) and PE conjugated 
W3/25 (CD4) and 0X 8 (CD8) (log10 PE signals) on X axis. Single colour 
fluorescence analysis using 0X 19 (CD5) detected by rabbit anti mouse 
FITC conjugate on X axis (log10FITC signal).
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Figure 4.5 Flow cytometric analysis showing CD5,CD4 and CD8 T cell 
depletion in the peripheral blood of DA graft recipients after R73 mAb 
treatement at days 4 and 7 after grafting. Two colour fluorescence analysis 
using FITC onjugated R73 on Y axis (log10 FITC signal) and PE conjugated 
W3/25 (CD4) and 0X 8 (CD8) (log10 PE signals) on X axis. Single colour 
fluorescence analysis using 0X 19 (CD5) detected by rabbit anti mouse 
FITC conjugate on X axis (log10FITC signal)
120
treated DA recipients of a Lewis heart graft at day 4 after transplantation, 
rising to 6.5%(SD 0.7, P= 0.002) in LNC and 3.4 (SD 1.8, P= 0.03) in PBL at 
day 7. CD 8 T cell numbers recovered to near normal at day 21 in LNC (mean 
14.5% SD1.0) and PBL (mean 9.5%, SD2.2). In our experiments CD8 +ve 
cells accounted for 12.9% (SD 1.8) of cells in the lymph nodes and 11.8% (SD
2.6) in peripheral blood of normal DA animals.
Activated CD4 T cells are critical for allograft rejection whereas graft rejection 
can progress in the absence of CD8 T cells (Grade et al, 1990). We therefore 
assessed whether there was a preferential depletion of CD4 T cells to account 
for graft tolerance in this model, however there was no significant difference in 
depletion of CD4 and CD8 cells at day 4 (student’s t test). At day 7, there was 
a trend towards preferential depletion of CD4 T cells at 64% in LNC and 89% 
in PBL compared to 50% and 75% for CD8 T cells though this did not reach 
statistical significance (P= 0.1, student’s t test). It appears therefore that 
although both CD4 and CD8 T cells are markedly depleted by R73, 
reconstitution of CD4 T cells is marginally slower and this may contribute to 
the induction of graft tolerance.
4:3 T cell receptor modulation after R73 mAb therapy
The most striking effect of R73 on the peripheral T cell pool is the depletion 
caused by the antibody. The depletion seen, however could be apparent if R73 
was in fact modulating the T cell receptor and so blocking the binding of the
121
R73-FITC conjugate used for detection of these cells. Figure 4.6 shows that 
there is evidence of TCR modulation at day 4 in the LNC and at days 7 and 21 
in peripheral blood. The graph also confirms the profound, though transient T 
cell depletion seen in this model.
4:4 Binding of R73 mAb to a/p TCR on T lymphocytes of R73 treated 
graft recipients
LNC were isolated from DA recipients of a Lewis heart allograft under cover 
of R73 treatment as before and incubated with rabbit anti-mouse (RAM) FITC 
conjugate and analysed by flow cytometry to assess R73 mAb binding at days 
4, 7, 21 and 100 after transplantation. The percentage of cells labelled with 
RAM-FITC was compared with the percentage of total CD5 +ve T cells (figure
4.7). The results show that at day 4 post transplant 81% of T cells in R73 
treated animals are bound by R73 mAb, however by day 7 R73 is detectable on 
only 52% of T cells. This may partly be due to CD4 and CD8 T cell recovery 
and partly due to internalisation of R73 by residual CD4 and CD8 lymphocytes 
which have not been depleted by mAb therapy.
TCR saturation of lymph node cells at day 4 and day 7 after R73 treatment and 
heart grafting was assessed in DA recipient animals by the comparing the peak 
fluorescence (PF) in LNC labelled with RAM-FITC with LNC firstly incubated 
with a saturating dose of R73 mAb. Figure 4.8 shows that at day 4 R73 mAb is 
bound to all available TCR ligands. At day 7, addition of further R73 results in
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Figure 4.6 TCR modulation in R73 treated graft recipients.
These graphs illustrate the comparative depletion of alpha/beta TCR +ve cells 
and cells expressing the pan T cell marker CD5 in lymph nodes (LNC) and 
peripheral blood (PBL). There is marked depletion of cells expressing both 
markers at days 4 and 7 with slightly increased depletion of TCR +ve cells 
suggesting modulation of the T cell receptor.
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Figure 4.7 R73 mAb binding to DA rat LNC after R73 mAb 
treatment and Lewis heart grafting. DA rat LNC were harvested on 
days 4, 7, 21, and 100 relative to receiving a Lewis heart allograft and 
200ug R73 day-2 and -1 prior to grafting. Cells were incubated with 
rabbit anti mouse FITC conjugate and analysed by flow cytometry. The 
results show that at day 4 81% of T cells(CD5 +ve) are labelled with 
R73 mAb. By day 7 R73 is bound to only 52% of T cells and by day 21 
no residual R73 is present.
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Figure 4.8 FACS histograms illustrating R73 mAb saturation 
in DA rat LNC at days 4 and 7 after transplant and R73 
treatment.Single colour flow cytometric analysis using rabbit 
anti mouse (RAM) FITC conjugate (a), shown on X axis, to 
detect bound R73 mAb on lymph node cells (log10 FITC signal). 
Unoccupied R73 binding sites detected(b) by adding a 
saturating dose of R73 mAb to LNC in vitro followed by RAM 
FITC conjugate.
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an increase in the PF and height of the peak suggesting that the majority of R73 
binding sites are unoccupied.
4:5 Effect of delaying Lewis heterotopic heart transplantation by 7 days 
into R73 treated DA recipients.
In the light of these results, Lewis hearts were transplanted into R73 DA 
recipients with a delay of 7 days relative to R73 treatment. Figure 4.9 shows 
that the majority of grafts are accepted indefinitely in the delayed transplant 
group ( MST >100 days). These data indicate that permanent graft acceptance 
can be induced in this model even at a point where only 50% of T cells are 
bound by R73 and when the majority of a/ft TCR binding sites on the surface 
of the T cell are unoccupied.
4:6 Immunohistochemical analysis of graft infiltrating cells.
In order to further clarify the potential mechanisms involved in this model we 
carried out immunohistochemical staining of cryostat sections of heart grafts 
removed from R73 treated graft recipients and untreated animals rejecting their 
grafts.
Briefly, R73 treated Lewis heart graft recipients (n=3) and untreated control 
animals rejecting their grafts (n=4) were killed at day 7 after transplant and the 
heart graft removed and snap frozen in liquid nitrogen. 5 p. sections were cut
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Fig 4.9 Effect of delaying heart transplant following treatment 
with R73 mAb. DA rats were given 200ug of R73 mAb as before 
and then a Lewis heart allograft either 24 hours after the last dose 
of antibody or 7 days later. 60% of recipient animals undergoing 
delayed transplant accepted their grafts indefinitely compared to 
80% in the group transplanted at 24 hours.
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onto triple well glass slides and fixed in ethanol. The cryostat sections were 
then labelled with mouse monoclonal antibodies to various cell surface markers 
(table 4.2) which were then detected using a biotin conjugated rabbit anti 
mouse mAb and stained using an HRP technique as described in chapter 2 
(materials and methods).
Monoclonal antibody cell surface marker
MRCOX8 CD8+ve cells
W3/25 CD4+ve cells
R73 a/pTCR+ve cells
MRC 0X39 IL2Ra
EDI macrophages, monocytes, dendritic cells
Table 4.2 Monoclonal antibodies used in immunohistochemical analysis of 
heart graft cellular infiltrates.
The results of immunohistochemical staining are shown in figure 4.10. There is 
a marked reduction in the degree of cellular infiltration of CD4 and CD8 T cells 
at day 7 in R73 treated animals which correlates with the T cell depletion noted 
in blood and lymph nodes. R73 (a/pTCR) expression is also markedly reduced 
in treated animals compared to rejecting grafts. This is probably due to 
combination of cell depletion and blocking of the a/pTCR in the grafts by R73 
mAb. IL-2Ra expression is also reduced in R73 treated grafts. This could be
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Figure 4.10 Cell infiltrates in Lewis heart grafts day 7 
after transplantation into R73 treated or unmodified 
DA recipients. Heart grafts from R73 treated animals and 
rejecting controls were removed on day 7. Cryostat sections 
labelled with the mouse anti-rat mAb’s as shown. Fewer CD4+ve 
(W3/25) and CD8+ve (OX8) cells were found in R73 treated hearts. 
IL2R (0X39) expression is also significantly lower in the treated 
group of animals. There were also significantly fewer macrophages 
(EDI) present in the R73 treated infiltrates.
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due to a reduction in T cells expressing the receptor sub unit or due to the 
presence of anergic cells which are unable to produce IL-2. Surprisingly the 
monocyte infiltrate in the R73 grafts is less than half that in the rejecting grafts. 
R73 mAb does not directly bind to monocytes and macrophages and so this 
observation can be explained by lack of pro inflammatory cytokine in a graft 
depleted of CD4 +ve helper T cells.
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4:7 Discussion
The aim of the experiments reported in this chapter was to determine the effect 
of R73 mAb on peripheral T cell subsets and to ascertain what proportion of 
peripheral T cells were coated with R73 and for how long during the early post 
transplant period. We also investigated whether R73 treatment resulted in TCR 
modulation and whether the effects on peripheral T cells were reflected by 
infiltration of the heart grafts themselves.
The experiments reported here demonstrate that after a brief course of R73 
treatment there is marked but partial, transient depletion of CD4 and CD8 T 
cells in peripheral blood and lymph nodes of R73 treated graft recipients. The 
associated depletion of CD5 +ve cells suggests that this is at least in part, 
actual cell depletion rather than purely modulation of the a/p  TCR by R73 
binding. By day 7 post transplantation CD4 and CD8 T cell numbers are 
increasing, with almost complete reconstitution by day 21 post transplantation 
with out loss of the heart allograft. In addition R73 was detectable on T cells 
up to 7 days post transplant. This suggests that the treatment dose of R73 in 
this model is sufficient to induce peripheral T cell depletion and coating of T 
cells during the period when acute rejection would normally be taking place. It 
is probable that the lower dose of 50|ig of R73 used in chapter 3 was 
unsuccessful in inducing permanent graft acceptance due to either insufficient T 
cell depletion or due to unoccupied a/pTCR binding sites in the early post 
transplant period. It is also not surprising that 500pg R73 did not positively
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influence graft survival as depletion of T cells is profound using 200jig and also 
TCR saturation is obtained with the 200|ig dose used in these experiments. 
Other groups have reported similar transient T cell depletion after pre 
transplant treatment with R73 without loss of the graft (Tsuchida et al, 1994, 
Heidecke et al, 1995) and also after R73 treatment of experimental established 
adjuvant arthritis (Yoshino and Cleland, 1992). Dufter and colleges, however 
found that in their model of R73 induced transplant tolerance that indefinite 
graft survival was only obtained if antibody treatment was continued for 70 
days after transplantation (Dufter et al, 1994). The transient depletion and loss 
of circulating treatment antibody after 7 days is in stark contrast to reports 
using anti-CD4 monoclonal antibodies. Transplantation tolerance using MRC 
OX-35 mAb to deplete CD4 T cells only occurs if depletion is present for 
greater that 40 days after transplantation (Herbert and Rosser, 1988). Darby 
and colleagues demonstrated that KT6 rat anti-mouse CD4 mAb could induce 
indefinite graft survival in mice without depletion of peripheral CD4 T cells, 
however prolonged presence of circulating antibody was required (Darby et al, 
1992).
There is, however evidence of TCR modulation in the residual T cells at days 4 
and 7 after transplantation suggesting that alloantigen recognition by the 
remaining T lymphocytes may be impaired and it is possible that these cells are 
in fact unresponsive or that they are subject to some form of immune 
regulation. This theory is supported by the observation that transplanting a 
heart graft in to R73 treated recipients eight days after completion of antibody
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treatment (day 7 in relation to normal R73 treated transplants) when less than 
50% of the remaining T cells are bound by R73 mAb and when peripheral T 
cell numbers are returning towards normal levels still results in indefinite graft 
survival. It may be that R73 treatment results in the deletion of antigen specific 
T cells and the remaining T cells, resistant to R73 treatment, regulate or 
suppress the function of the new population of CD4 and CD8 T cells. There is 
much evidence to support the presence of regulatory T cells in mAb induced 
models of transplantation tolerance and in a physiological role such as mucosal 
immunity. Reports using anti CD4 mAbs have shown that once tolerance to a 
graft is established (4 weeks after stopping mAb therapy) tolerant T cells can 
be adoptively transferred into naive hosts and induce specific tolerance to a 
second graft (Waldman and Cobbald, 1993). This has been termed infectious 
tolerance. There is also increasing evidence that a specialised group of 
regulatory T cells (T reg) may be responsible for downregulation of immune • 
responses to both foreign and self antigens. Experiments investigating the 
prevention of a detrimental Thl response to enteric foreign antigens in mice 
have indicated that T reg cells may be CD4+ CD45Rblow and induced by 
transforming growth factor beta (TGF0) (Powrie et al, 1993 and 1994). 
Regulatory CD8 T cells have also been described. Interestingly, these cells 
appear to be TCRy/5 positive T cells as oral tolerance is abrogated in mice 
lacking y/5 T cells (Ke et al, 1996). It has also been demonstrated that 
protection from diabetes induced by insulin aerosols can be transferred by 
adoptive transfer of y/5 T cells from diabetes resistant NOD mice to syngeneic
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hosts (Harrison et al, 1996). This observation is of particular relevance to the 
work of this thesis since R73 mAb only binds to a/p  T cells and y/5 T cells 
would therefore be spared from the depletion caused by R73 treatment. It is 
therefore possible, though not tested in this thesis, that the R73 resistant 
regulatory T cells responsible for indefinite graft survival in this model are in 
fact y/5 T cells. Another potential population of regulatory cells are those 
CD4+ T cells which constitutively express CD25 (IL-2Ra). Congenital absence 
of these cells results in the development of autoimmune diseases in mice and it 
may be that failure to deplete these cells completely with R73 mAb results in 
downregulation of the alloimmune response (Hunig and Schimpl, 1997).
It has been demonstrated that CD4 T cells but not CD8 T cells are required for 
rejection of an allograft (Grade et al, 1990, Bolton et al, 1989). In the 
experiments described above, CD4 T cells appear to be preferentially depleted 
at day 7 post transplant and this prolongation of CD4 depletion may contribute 
to prolongation of graft survival.
It is interesting to note that R73 treatment resulted in significantly increased T 
cell depletion in peripheral blood compared to lymph nodes. This may be due to 
impaired R73 access into the lymph nodes compared to peripheral blood or 
perhaps R73 activity is more pronounced against circulating cells compared to 
the more sessile LNC. It is also possible that LNC contain a population of R73 
resistant T cells or indeed R73 induced regulatory cells.
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Although analysis of LNC and peripheral blood allows detailed investigation of 
the immunological effects of R73 treatment, it is essential to determine the 
effects of R73 treatment on the cell populations within the heart graft. Analysis 
of the cellular infiltration of the grafts themselves at day 7 was therefore carried 
out using an immunoperoxidase technique. This revealed a reduction in CD4 
and CD8 T cell infiltration compared to rejecting grafts and also reduced 
macrophage infiltration and IL-2R expression. These findings can be explained 
by the reduction in circulating T cells seen at this time point which would 
normally be available for recruitment in to the graft. These observations are 
comparable to those reported by Heidecke and colleagues in their model of 
cardiac transplantation in sensitised animals (Heidecke et al, 1995).
The results described in this chapter imply that indefinite graft survival induced 
by R73 mAb is due at least in part to peripheral T cell depletion and subsequent 
reduction in graft infiltration by effector cells, however other peripheral 
mechanisms particularly T cell suppression, depletion of alloreactive T cells and 
T cell anergy are also likely to play an important role in prolonging graft 
survival.
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4:8 Summary
4:2:1 Flow cytometric analysis of T cells expressing the rat pan T cell marker 
CD5 (detected by MRC 0X19) reveals transient depletion of T cells to one 
third of normal in the lymph nodes of R73 treated DA recipients of a Lewis 
heart allograft at days 4 and 7 post transplant. R73 mAb is significantly more 
effective in depleting T cells in the peripheral blood than in the lymph nodes.
4:2:2 CD4 +ve T cells are also depleted to a similar extent in the lymph nodes 
and peripheral blood of R73 treated animals with recovery to 50% of normal by 
day 7 post transplant and recovery to normal levels by day 21.
4:2:3 CD8 +ve T cells in the peripheral blood and lymph nodes are transiently 
depleted with reconstitution to normal numbers by day 21 post transplant. The 
recovery of CD8 T cells appears to be marginally quicker than CD4 T cells.
4:3 R73 mAb treatment results not only in transient T cell depletion but also in 
modulation of the a/(3 T cell receptor and so may impair TCR ligation with 
MHC/peptide on donor APC.
4:4 R73 mAb is bound to 81% of peripheral T cells at day 4 post 
transplantation, however by day 7, only 50% of cells have detectable bound
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R73. In addition at day 4 all available TCR binding sites are occupied by R73 
but by day 7 the majority of TCR binding sites are available for MHC ligation.
4:5 Delaying heart transplantation by 7 days after completion of R73 treatment 
when there is only 50% T cell depletion and the majority of TCR binding sites 
are unoccupied by antibody still results in indefinite graft survival in the 
majority of treated animals suggesting that depletion is not the only mechanism 
responsible for indefinite graft survival in this model.
4:6 Immunohistochemical analysis of heart grafts from R73 treated recipients 
and rejecting controls at day 7 after transplant shows a marked reduction in 
cellular infiltrate in grafts from treated animals
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CHAPTER FIVE
In Vitro Characterisation of Rat Lymphocytes after R73
Treatment
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5:1 Introduction
The results described in the previous chapters show that pre graft treatment of 
recipient DA rats with R73 mAb results in indefinite cardiac allograft survival 
in the majority of animals and that this is associated with marked but 
incomplete CD4 and CD8 T-cell depletion in the early post transplant phase. 
However, T cell populations begin to recover by day 7 and are almost 
completely restored by day 21 without the loss of the graft suggesting that the 
nature of the T-cell response to alloantigen has been altered. The observation 
that thymectomy does not abrogate the graft acceptance implies that the 
peripheral T-cell pool is subject to some form of immune modulation. The 
Thl/Th2 polarisation of CD4 helper T cells has been discussed in the 
introductory chapter of this thesis. T helper cells producing predominantly IL-2 
and IFNy are termed Thl cells and are typically responsible for the promotion 
of cell mediated immune responses, while Th2 cells produce IL-4 and IL-10 
and IL-13 and are predominantly responsible for humoral immunity. IL-2 
production by graft infiltrating cells is reduced in animals tolerant to renal 
allografts after allogeneic blood transfusion and administration of exogenous, 
recombinant IL-2 abrogates tolerance in this model (Dallman et al, 1991). 
Other strategies for induction of transplant tolerance such as anti-CD4 
treatment, and selective coreceptor blockade using CTLA4Ig have resulted in 
the predominance of Th2 type cytokines in the grafts of tolerant animals 
(Nickerson et al, 1993, Sayegh et al, 1995, Mottram et al, 1995). These
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experiments have led to the hypothesis that graft tolerance is associated with 
polarisation towards a Th2 type response and rejection is associated with a 
predominance of Thl cells. Although polarisation towards a Thl or Th2 
cytokine profile has been proposed as mechanism for peripheral tolerance or 
rejection respectively several studies have shown that failure to express these 
cytokines does not inevitably lead to rejection or long term engraftment 
(Larsen et al, 1996, Steiger et al, 1995).
The model of long term graft acceptance induced by R73 mAb is characterised 
by marked early depletion of CD4 and CD8 T cells. This depletion is transient, 
however, and T cell numbers are recovering by day 7 post transplant and return 
to near normal by day 21 without evidence of rejection of the heart graft. One 
possible explanation for this would be that the remaining T cells have been 
polarised towards a Th2 response allowing continued graft acceptance. In the 
following experiments, this hypothesis is tested by measuring the cytokine 
production by R73 treated graft recipient LNC in vitro. This was done by 
further stimulating the DA graft recipient LNC in vitro using irradiated Lewis 
stimulators and estimating the proliferative response of these cells and the 
cytokine production in the cell culture supernatants. Evidence for differential 
expression of cytokine genes in non rejecting (R73 treated) compared to 
rejecting (untreated) heart allografts was sought by semiquantitively measuring 
cytokine messenger RNA in heart grafts using RT-PCR.
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5:2 In vitro proliferation of R73 treated graft recipient LNC
DA rat LNC from R73 treated graft recipients, unmodified graft recipients and 
normal ungrafted animals were isolated as described in Chapter 2 (materials 
and methods). The cells were harvested from treated animals on days 4, 7, 21 
and 100 after receiving a Lewis heart allograft. These cells were then cultured 
in 96 well plates with irradiated spleen cells from normal Lewis rats and 3rd 
party PVG rats as stimulators and with the mitogen concanavalin A (conA) as a 
positive control. Cells were harvested 72, 96 and 120 hours after incubation 
and proliferation determined by (3H) thymidine incorporation as previously 
described in Chapter 2 (materials and methods). All experiments were carried 
out at least three times except at the day 21 time point when they were carried 
out twice. Proliferation data are expressed as the means and standard 
deviations of peak proliferation in the multiple experiments for each group of 
animals. Proliferation is expressed as a proliferation index (PI) which is the 3H 
thymidine incorporation in the lymph node cells in counts per minute (CPM) in 
responder LNC proliferating under experimental conditions divided by the 
CPM of responder LNC cultured in medium alone. Proliferation was expressed 
in this form to facilitate easy comparison between experimental groups. Cell 
culture supernatants from duplicate proliferation experiments were removed at 
72 hours post stimulation for analysis of IL-2 and IFNy production by bioassay. 
Data were analysed using the Mann-Whitney U test where appropriate 
comparing treated groups with naive animals.
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Figure 5.1 illustrates that LNC from R73 treated graft recipients harvested on 
days 4 post transplant showed significantly reduced proliferation to donor 
strain Lewis (P=0.01), 3rd party PVG stimulators (P=0.05) and conA (P= 
0.001) compared to normal DA rats and unmodified rejecting controls. LNC 
removed on days 7, 21 and 100 post transplant from R73 treated graft 
recipients proliferated normally to each of the stimulators compared to normal 
DA and rejecting controls.
5:3 In vitro cytokine production by LNC from R73 treated graft 
recipients
Supernatants were harvested from allogeneic MLR at 72 hours post incubation 
and bioassay carried out to determine IL-2 production and capture ELISA used 
to measure IFN-y production by in vivo R73 treated LNC in response to 
further allogeneic challenge by irradiated Lewis stimulators. The results are 
illustrated in Figure 5.2. IL-2 production by R73 treated responders is 
significantly reduced at days 4 (P= 0.008) and 7 (P= 0.002) post transplant but 
is once again detected at days 21 and 100 though the levels found at day 100 
are still significantly reduced compared to normal untreated DA rats (P= 
0.001). IFN-y production was detected at similar levels at each time point by 
both R73 treated and normal untreated responders.
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Figure 5.1 In vitro proliferation of R73 treated graft recipient 
LNC. DA lymph node cells from R73 treated graft recipients were 
isolated at various time points and MLR performed using irradiated 
splenocytes as stimulators from donor strain Lewis and 3rd party PVG 
rats and the and results expresed as an index of background 
proliferation (PI). R73 treated animals at day 4 show significantly 
reduced proliferation to both donor and 3rd party stimulators but at day 
7 R73 treated cells are able to proliferate normally to donor 
specific, 3rd party and mitogemc stimulation. ( * P= 0.001, ** P= 0.01. 
*** p= o.05, Mann-Whitney U test compared to naive animals)
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Figure 5.2 In vitro production of the Thl cytokines IL2 
and IFNgamma. Supernatents were isolated from MLR at 72 
hours and IL-2 and IFN gamma production by LNC from R73 
treated graft recipients and naive DA rats detected by 
bioassay. LNC from day 4 and day 7 treated graft recipients 
appear unable to produce IL-2 in response to further allogeneic 
stimulation in vitro and IL-2 production remains suppressed 
even at day 100 after grafting. LNC retain their ability to 
produce IFN gamma at all time points.* Mann-Whitney U test.
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These data suggest firstly that LNC from R73 treated graft recipients do not 
produce IL-2 in response to further antigenic challenge. This may be due to 
depletion of alloreactive T cells or the T cells present in the MLR are able to 
proliferate but incapable of producing IL-2. This theory is supported by the fact 
that IL-2 production is impaired even at days 21 and 100 post transplant. 
Another possible explanation is polarisation towards a Th2 response, however 
we could not assess the presence of IL-4 and IL-10 in these supernatants due 
to the lack of a reliable bioassay for these cytokines in the rat.
Lymph node cells from R73 treated animals produced IFNy in quantities 
comparable with normal DA and rejecting LNC. There are several possible 
explanations for this observation. Functional NK cells capable of IFNy 
production may predominate in the lymph nodes of R73 treated animals at the 
first 4 days after transplantation, however LNC from R73 treated graft 
recipients are capable of producing IFNy at day 100 post transplant indicating 
that the T cells responsible for maintenance of tolerance in this model may have 
a ThO phenotype.
5:4 Cytokine gene transcripts in heart grafts from R73 treated graft 
recipients
The analysis of cytokine production by R73 treated animals shown above 
reflects the characteristics of the lymph node cells isolated from these animals. 
It may be, however, that the cytokine production at the site of antigen
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recognition, i.e. the graft itself may be more relevant. In addition bioassays can 
be very non specific and interpretation of the results should be cautious.
We therefore attempted to analyse cytokine production in the graft itself using 
semiquantitative RT-PCR. This technique lends itself well to the localised 
detection of the induction of cytokine genes and has been used in transplant 
models to outline the pattern of cytokine production in allogeneic and 
syngeneic heart transplantation in mice (Dallman et al, 1991). In this 
experiment Lewis heart grafts were removed from R73 treated DA recipients 
on days 4, 7, 21 and 100 after transplantation and on days 4 and 7 from 
rejecting control animals. Normal Lewis hearts were analysed for comparison. 
Hearts were divided and immediately snap frozen in liquid nitrogen until RT- 
PCR analysis (materials and methods). Data are expressed as the average 
number of PCR cycles at which mRNA was detected for each time point. 
Statistical comparison was carried out using the Mann-Whitney U test.
5:4:1 IL2 and IFNy cytokine message in heart grafts from R73 treated DA 
recipients.
The results of the analysis for the Thl cytokines IL-2 and IFNy are shown in 
figure 5.3. There is significantly increased expression of IL-2 gene (P= 0.0005) 
and IFNy gene (P= 0.004) in the grafts of rejecting animals at day 4 post 
transplant in comparison to normal hearts and those from R73 treated animals.
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Figure 5.3 IL2 and IFN gamma cytokine mRNA in heart grafts from 
R73 treated DA recipients. Heart grafts were removed from R73 treated 
recipients and unmodified control animals rejecting their grafts at days 4, 7 
and 100 after transplant and cytokine mRNA detected by semiquantitative 
PCR. IL2 and IFNgamma expression is significantly increased in the grafts of 
animals rejecting their grafts at day 4 compared to R73 treated animals. EL2 
and IFNgamma production is increased in both treated and rejecting animals 
at day 7 and return to normal levels by day 100. * Mann-Whitney U test 
compared to R73 treated and normal animals.
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At day 7, EL-2 and IFNy gene expression in R73 treated and rejecting grafts is 
elevated compared to normal Lewis hearts. By day 100 post transplant, EL-2 
and EFNy expression have returned to baseline levels.
5:4:2 EL4, IL10 and IL13 cytokine message in heart grafts from R73 
treated graft recipients.
Figure 5.4 shows the results of PCR detected mRNA for the Th2 cytokines IL- 
4, EL-10 and EL-13 in heart grafts from R73 treated recipients. Message for 
each of these cytokines was detectable at high levels in all experimental groups 
including normal Lewis hearts using this technique. There was no significant 
difference between R73 treated DA graft recipients and normal or rejecting 
animals.
5:5 Expression of IL-2 receptor subunits in heart grafts from R73 treated 
graft recipients.
The IL-2 receptor is a 15.5 kDa glycoprotein consisting of three subunits 
distinguishable by their affinity for ligand- EL-2Ra. IL-2R0 and IL-2Ry. 
Upregulation of the EL-2 receptor is a critical step in the activation of 
alloreactive T cells and impaired expression of this receptor or its subunits by T 
cells has been shown to result in T cell anergy and tolerance to alloantigen 
(Dallman et al, 1991).
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Figure 5.4 IL4, IL10 and IL13 cytokine mRNA in heart 
grafts from R73 treated recipients. Heart grafts were 
removed from R73 treated recipients and unmodified control 
animals rejecting their grafts at days 4, 7 and 100 after 
transplant and cytokine mRNA detected by semi quantitative 
PCR. IL4, IL10 and IL 13 message in both treated and rejecting 
animals was detected in all groups and was comparable to that 
found in normal Lewis hearts.
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We assessed expression of IL 2Ra and p mRNA in R73 treated and rejecting 
heart grafts at days 4, 7 and 100 post transplant using RT PCR. Hearts were 
prepared as for PCR cytokine analysis and PCR methods were as above.
Significant upregulation of both alpha and beta IL-2 receptor subunits was seen 
in rejecting grafts at day 4 post transplant (P= 0.01) consistent with activation 
of allogeneic T cells and at day 7 (P= 0.03) in the R73 treated grafts. There 
was no evidence of increased IL-2R gene expression at days 4 and 100 post 
transplant in the R73 treated grafts compared to normal animals (figure 5.5).
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Figure 5.5 Expression of IL2 receptor subunits in heart grafts 
from R73 treated graft recipients .Heart grafts were removed from 
R73 treated recipients and unmodified control animals rejecting their 
grafts at days 4, 7 and 100 after transplant and IL2R mRNA detected 
by semiquantitative PCR. Grafts from R73 treated and unmodified 
rejecting rats show significant upregulation of EL2 receptor subunits 
compared to normal Lewis hearts at day 7 post transplant. * Mann- 
Whitney U test.
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5:6 Discussion
The results presented in chapters three and four of this thesis demonstrate that 
permanent heart graft survival can be obtained using a pre transplant R73 
treatment regime in the Lewis-DA rat strain combination. This is associated 
with transient and incomplete peripheral T cell depletion. The experiments 
carried out in this chapter attempt to define whether those cells which remain 
after R73 treatment play a role in perpetuating continued tolerance to the graft. 
Ligation of the T cell receptor with allogeneic MHC+peptide along with 
coreceptor interaction results in proliferation of CD4 and CD8 T cells. The first 
set of experiments described in this chapter show that LNC removed from R73 
treated graft recipients at day 4 post transplant proliferate poorly in MLR when 
stimulated by irradiated allogeneic and 3rd party stimulators. LNC removed on 
days 7, 21 and 100 proliferate normally. These observations can be explained 
firstly on the basis of the profound T cell depletion seen at day 4. Since the 
MLR experiments were carried out using unseparated LNC responders, 
responder cells at day 4 will be mainly B cells and NK cells which proliferate 
poorly to allogeneic stimulation in the absence of T cell help. In addition, the 
smaller proportion of lymphocytes present in the MLR may result in a shift in 
peak proliferation outwith the time points measured. The results at days 7, 21 
and 100 reflect the T cell recovery seen on flow cytometric analysis along with 
absence of R73 mAb at these time points. It may seem paradoxical that T cells 
are tolerant of a Lewis heart allograft in vivo yet proliferate to donor specific 
allogeneic stimulation in vitro, however the LNC have been removed from a
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tolerogenic environment and perhaps there are peripheral, circulating 
“regulatory” or “suppressor” T cells induced by transplantation under cover of 
R73 that maintain the graft but fail to influence LNC in vitro. Tsuchida and 
colleagues have noted in their model of R73 induced graft tolerance that T cells 
from R73 treated graft recipients proliferate in MLR when stimulated by 
allogeneic heart cells but not to allogeneic or third party spleen cells. Their 
explanation for this finding was that expression of certain peptides is tissue 
specific and that tolerance may only be induced to heart specific antigens plus 
MHC (Tsuchida et al, 1994).
The use of tolerising therapies has been shown in various experimental models 
to result in immune deviation towards a Th2 type response. However, some 
experiments have shown that the presence of IL-4 in the absence of IL-2 and 
EFNy does not necessarily lead to graft tolerance. As an explanation for these 
observations, it has been suggested that all T cell growth factors can, in high 
concentration stimulate a rejection response and as a result the cytokines IL-2 
and IL-4 both present barriers to tolerance with IL-4 a weak barrier and IL-2 a 
strong barrier (Strom et al, 1996).
Patterns of specific cytokine production by R73 treated graft recipients were 
therefore investigated in this chapter by assay of IL-2 and IFNy production by 
restimulated LNC in allogeneic MLR and by detection of cytokine mRNA in 
the heart grafts. In this R73 model, lymphocytes from animals receiving R73 
therapy do not produce IL-2 after further allogeneic stimulation in vitro but are 
able to produce IFNy normally. On examination of cytokine gene expression in
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the allografts themselves by RT-PCR, we found that IL-2 and IFNy message 
could be detected in hearts from R73 treated animals though in lower amounts 
than in grafts undergoing rejection at similar time points. We also detected IL- 
4, IL-10 and IL-13 message in both rejecting and R73 treated grafts at all time 
points. It must be stressed, however that the results of PCR experiments such 
as these are at best semiquantitative and that mRNA levels may not accurately 
predict levels of biologically active cytokine. This is because cytokine genes are 
subject to post transcriptional regulation and therefore gene expression does 
not necessarily correlate with protein production. It is therefore possible that 
IL-2 production within the graft is reduced due to post transcriptional 
regulation of the IL-2 gene, perhaps as a result of R73 mAb therapy. It has 
been suggested that this may occur due to cross linking of TCR molecules by 
R73 prior to encountering alloantigen and subsequent induction of an anergic 
state (Heidecke et al, 1996).
A critical step in T cell activation is the upregulation of the IL-2 receptor (IL- 
2R) and as a result this receptor has become a target for immunotherapy in 
transplantation (Waldmann, T, 1993, Waldmann and O’Shea, 1998). 
Messenger RNA for IL-2Ra and J3 subunits was detectable by RT-PCR in both 
R73 treated and rejecting grafts in our experiments with higher expression at 
day 4 in rejecting grafts and similar levels at day 7. Taking these results in 
conjunction with the above cytokine profiles and the results from 
immunohistochemical analysis of graft infiltrates in chapter 4, it is possible that 
although transcription of the IL-2R gene takes place, expression of IL-2R
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protein may be prevented perhaps through altered signalling through the T cell 
receptor induced by R73.
Bearing these points in mind, it appears that R73 mAb treatment of heart graft 
recipients results in the production of T cells incapable of normal levels of IL-2 
production despite the presence of IL-2 mRNA in the heart grafts. These cells 
are capable of IFNy production and the graft infiltrating cells express the Th2 
cytokine genes for IL4, IL10 and IL13. This suggests that the barrier to 
tolerance induction by IL-2 is removed either by polarisation of CD4 helper T 
cells towards a Th2 type response or by the induction of anergy in potentially 
alloreactive T cells leaving the relatively weak barrier of IL-4 to the induction 
of allograft tolerance. Anti CD4 treatment protocols in rodents have in some 
cases resulted in similar patterns of immune deviation (Binder et al, 1996, 
Mottram et al, 1995), however other anti-CD4 models have shown no evidence 
of Thl/Th2 shift (Jaques et al, 1998). Strategies which block coreceptor 
interaction, particularly B7-CD28 using CTLA4Ig, have resulted in inhibition 
of Thl cytokines with sparing of Th2 cytokines (Sayegh et al, 1995). 
Interestingly, recent studies using Fc receptor non binding anti-CD3 
monoclonal antibodies have reported suppression of allograft rejection 
associated with cytokine deviation and Thl cell inactivation (Smith and 
Bluestone, 1997). The authors of this report suggest that the action of this anti- 
CD3 fusion protein is due to partial signalling through the T cell receptor 
resulting from partial phosphorylation of the CD3 £ chain and subsequently
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incomplete phosphorylation of ZAP-70. Studies using altered peptide ligands 
(APLs) and co-receptor blockade to provide sub optimal antigenic ligand for 
the TCR have also resulted in partial T cell signalling, rendering T cells 
unresponsive or anergic (Sloan-Lancaster, et al, 1993 and 1994, Madrenas et 
al, 1995). One could therefore propose that R73, anti-TCR mAb exerts its 
effect, at least in part, by binding to the TCR and inducing a partial signal 
through the T cell receptor resulting in cytokine deviation and Thl cell 
inactivation.
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5:7 Summary
5:2 LNC from R73 treated graft recipients harvested 4 days after 
transplantation proliferate poorly in vitro to both allogeneic and 3rd party 
stimulation. LNC’s harvested R73 treated graft recipients on days 7, 21 and 
100 however are able to proliferate normally in MLR when stimulated by 
allogeneic and 3rd party stimulators.
5:3 LNC from R73 treated graft recipients are unable to produce IL-2 when re 
stimulated in MLR at day 4 after transplant and IL-2 production is impaired on 
days 7, 21 and 100 after transplant. IFNy production is not impaired after R73 
treatment.
5:4 Semiquantitative PCR analysis of cytokine mRNA transcripts in heart 
grafts from R73 treated and rejecting animals shows increased mRNA for IL-2 
and IFNy in rejecting animals compared to R73 treated and normal Lewis 
hearts. Transcripts for IL-2Ra and (3 were also increased in rejecting grafts. 
Messenger RNA for IL-4, IL-10 and IL-13 was detected in similar amounts in 
all groups.
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CHAPTER SIX
Apoptosis in lymph nodes and heart grafts after R73 treatment
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6:1 Introduction
Since the discovery of apoptosis in 1972 a great deal of research has been 
carried out to elucidate its role in several biological and pathological processes 
including transplantation, oncology, HIV and autoimmunity. Apoptosis is a 
mode of cell death in which the cell undergoes a distinctive pattern of 
morphological and molecular changes activated by the cell itself. The cell 
rapidly dehydrates forming a tight sphere with a convoluted membrane. 
Chromatin condensation occurs at the periphery of the nucleus followed by 
disruption of the nuclear membrane. Endonucleases then clip chromosomes at 
180 base intervals resulting in DNA fragments of oligonucleosomal length 
(Arends et al, 1990). The nuclear fragments and cytoplasmic contents are then 
packaged into apoptotic bodies surrounded by plasma membrane and 
phagocytosed by surrounding cells. During apoptosis there is upregulation of 
certain genes which appear to be required for the process to occur as well as 
increased protease activity (Wyllie et al, 1984). Apoptotic cells can be detected 
histologically and on electron microscopy by their characteristic appearance 
and hyperchromicity and the DNA 3’ ends can be labelled with a biotinylated 
thymidine analogue (TUNEL). The DNA fragments stain well with 
fluorochromes such as propidium iodide (PI) and can be detected by flow 
cytometry. The products of DNA degradation are of the size of nucleosomal 
and oligonucleosomal fragments and so form a characteristic ladder pattern on 
gel electrophoresis.
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Since its first description in 1972 (Kerr et al, 1972) the process of apoptosis 
has been extensively investigated particularly in the field of embryology where 
it has been found to be essential for normal development (Sulston and Horvitz, 
1977). In the immune system, apoptosis plays an important physiological role 
in limiting the size and duration of the primary T cell immune response and in 
negative selection of autoreactive T cells in the thymus (Surh and Sprent, 
1994). In addition it has been suggested that CD4 effector T cells kill their 
targets by inducing apoptosis (Hanabuchi et al, 1994, Kagi et al, 1994).
The role of apoptosis in acute allograft rejection is at best unclear. Bergese and 
colleges found that the pattern of apoptosis in rejecting murine allografts was 
inconsistent with parenchymal tissue damage as high levels were found in both 
rejecting and accepted grafts (Bergese et al, 1997). It has been suggested that 
apoptosis is associated with spontaneously accepted liver grafts in mice and 
may be responsible for both the elimination of alloantigen expressing donor 
cells during rejection and the elimination of cytotoxic T cell clones from the 
graft in a model of rat liver and small bowel transplantation (Meyer et al, 
1998). In addition, it is thought that apoptosis conveys immunological privilege 
to certain sites in the body such as the testes and the eye (Bellgrau et al, 1995).
It has recently been documented that several receptor molecules may be 
responsible for initiating apoptosis in T cells and their targets. The TCR/CD3
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complex, CD95 (Fas or Apo-1), Thy-1, CD2 and MHC class I have all been 
implicated in triggering programmed cell death in T cells and the specific 
conditions required for this to take place are being extensively investigated 
(Itoh, et al, 1991, Ju et al, 1994, Rouleau et al, 1997, Woodle et al, 1997, Wu 
et al, 1997). Immature T cells in the thymus undergo apoptosis on ligation of 
their TCR whereas mature, resting T cells undergo proliferation and produce 
EL-2 on TCR ligation. Interestingly, it has been noted that mature activated T 
cells are susceptible to TCR mediated apoptosis and it has been proposed that 
this completes a feedback loop whereby antigen stimulation induces T 
lymphocyte activation and growth factor production, growth factors stimulate 
cell cycle progression which in turn predisposes to TCR mediated cell death 
with strong TCR engagement activating the apoptotic process (Van Parijs et al, 
1996, Cohen et al, 1996).
In our model of graft acceptance using R73 anti-TCR mAb treatment, the 
possibility exists that TCR ligation of activated lymphocytes by R73 mAb may 
play a part in the maintenance of tolerance by inducing apoptosis in alloreactive 
T cells. The experiments described in this chapter quantify apoptosis seen in the 
lymph nodes and heart grafts of R73 treated DA recipients of Lewis heart 
grafts.
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6:2 Flow cytometric analysis of apoptotic cells in the lymph nodes of R73 
treated graft recipients
Quantification of apoptotic cells in heterogeneous tissue such as lymph nodes 
can be difficult, however flow cytometric analysis using propidium iodide (PI) 
labelling of DNA strands allows us to compare the proportion of lymph node 
cells undergoing apoptosis in normal, R73 treated and rejecting animals 
(Nicoletti et al, 1991, Dive et al, 1992). Briefly, LNC were harvested as 
previously described and stored at 4°C. Trypsin solution was added to tubes 
containing 106 cells to remove necrotic cells, isolated nuclei and late apoptotic 
cells followed by trypsin inhibitor and finally the PI solution. Stained cells were 
then analysed for PI fluorescence on a Coulter EPICS XL flow cytometer.
Figure 6.1 shows the cell cycle histogram obtained in normal DA rats. Cells are 
shown in the G0/G1, S and G2 phases of the cell cycle with cells displaying 
hypodiploid levels of fluorescence being regarded as apoptotic. The level of 
apoptosis is expressed as a percentage of the total number of cells analysed 
with 20,000 events per analysis. At least 4 animals were used in each group and 
the results compared using the Mann- Whitney U test.
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Figure 6.1 Cell cycle histogram showing phases of the cell 
cycle in normal DA rat LNC. G0/1 peak occurs at channel 200. 
The G2/M peak is set at 2x the G0/1 peak. S is between G0/1 
and G2/M. Sub diploid cells are regarded as apoptotic.
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6:2:1 Apoptotic lymph node cells in R73 treated graft recipients at day 4 
post transplant
At day 4 after heart grafting, the number of cells undergoing apoptosis in the 
lymph nodes of R73 treated graft recipients (mean 16.2%, SD 8.3) is slightly 
higher than that found in animals rejecting their allograft (mean 7.42%, SD 5.7) 
but this does not reach statistical significance. In addition, similar numbers of 
apoptotic cells are found in the LNC extracted from normal DA rats (mean 
16.6%, SD 10.3) and rats who received R73 but no allograft (mean 10.2%, SD 
2.7) (Figures 6.2 and 6.3).
6:2:2 Apoptotic lymph node cells in R73 treated graft recipients at day 7 
post transplant
At day 7 post transplant, however, DA rats receiving a Lewis heart allograft 
and R73 have a significantly higher number of cells undergoing apoptosis in 
their lymph nodes compared to all other groups of animals (mean 25.9%, SD 
8.3, P= 0.01) including DA rats rejecting their Lewis allografts (mean 8.7%, 
SD 2.7) and R73 treated rats at day4. Interestingly, the apoptosis appears to 
depend on the presence of a heart graft in addition to R73 treatment since naive 
DA rats given the same regime of R73 but no allograft show levels of apoptosis 
comparable to control, untreated animals. (Figures 6.4 and 6.5).
Table 6.1 compares apoptosis in LNC from R73 treated graft recipients at 
different time points. Apoptosis peaks at day 7 with levels comparable to
164
% 
ap
op
to
tic
 
ce
lls
3 0  i
2 5  -
20 -
1 5  -
10 -
R73+ graft rejectingnormal DA R73
no graft
Figure 6.2 Apoptotic lymph node cells in R73 treated graft 
recipients at day 4 post transplant. Lymph nodes cells were 
harvested from R73 treated DA recipients of a Lewis heart allograft 
and subjected to propidium iodide staining FACS cell cycle analysis 
to assess the proportion of cells undergoing apoptosis. Normal DA 
rats, DA rats rejecting their Lewis allograft and ungrafted R73 
treated animals were used as controls. No significant difference in 
numbers of apoptotic cells was detected in any of the groups at this 
time point.
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Figure 6.3 Cell cycle histograms showing apoptosis 
in LNC of R73 treated graft recipients on day 4 post 
transplant. LNC were stained with propidium iodide 
and analysed by flow cytometry. Histograms obtained from 
normal and rejecting DA animals are shown for 
comparison. Percentages shown are cells in the sub diploid 
region considered to be apoptotic.
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Figure 6.4 Apoptotic lymph node cells in DA rats on day 7 
relative to transplant. Lymph nodes cells were harvested from 
R73 treated DA recipients of a Lewis heart allograft and subjected 
to propidium iodide staining FACS cell cycle analysis to assess the 
proportion of cells undergoing apoptosis. LNC from normal DA 
rats, R73 treated DA rats without a graft and untreated rejecting 
graft recipients were used as controls. At day 7, apoptosis was 
highest in R73 treated graft recipients and significantly higher than 
animals rejecting their grafts at this time point. * Mann- Whitney U 
test compared to rejecting controls.
167
Normal DA Day 7 rejecting
11.4%
P . I .  FL3
12.9%
Day 7 R73 (a)
36.1%
gL>
Day 7 R73 (b)
P. I .  FL3
21.7%
P .I. FL3
Figure 6.5 Cell cycle histograms showing apoptosis 
in LNC of R73 treated graft recipients on day 7 
post transplant. LNC were stained with propidium 
iodide and analysed by flow cytometry. Histograms 
obtained from normal and rejecting DA animals are 
shown for comparison. Percentages shown are cells in 
the sub diploid region considered to be apoptotic.
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normal DA rats at days 4 and 100 relative to transplant. This suggests that both 
R73 mAb and alloreactive T cells are required for apoptosis in this model since 
no antibody is detectable at day 100 and T cell numbers are markedly depleted 
at day 4.
Day after transplant % apoptotic cells
normal DA rat 16.6, SD 10.4 NS
day 4 R73 treated 16.2, SD 8.4 NS
day 7 R73 treated 25.8, SD 8.2 P= 0.01*
day 100 R73 treated 17.2, SD 7.0 NS
Table 6.1 Apoptosis in LNC from normal DA rats and R73 treated graft 
recipients at various time points after grafting detected by flow 
cytometry. * Mann- Whitney U test
These data suggest that lymphocytes in R73 treated graft recipients are 
subjected to apoptotic signals in excess of normal and rejecting DA rats and 
that the presence of alloantigen is required for this process to take place since 
R73 treated animals with no heart graft exhibit levels of apoptosis comparable 
to control DA animals.
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6:3 Analysis of apoptotic cells in graft infiltrates using Terminal 
deoxynucleotidyl transferase mediated dUTP Nick End Labelling 
(TUNEL) of cryostat sections.
As a result of the DNA fragmentation by endonucleases seen in apoptosis, 
there are large numbers of DNA strand breaks which can be detected by 
labelling their 3' ends with digoxygenin conjugated nucleotides in a reaction 
catalysed by exogenous TdT.
In these experiments cryostat sections of transplanted Lewis hearts from R73 
treated and rejecting, untreated DA recipients were stained using TUNEL as 
described in chapter 2 and compared to sections from normal untransplanted 
Lewis hearts.
Sections were examined at x400 magnification and apoptosis quantified by 
counting TUNEL +ve cells in ten consecutive high power fields. The tissue 
distribution of TUNEL +ve cells was also noted in the sections. The data are 
expressed as the means and standard deviations of 3 or 4 animals in each 
group. Statistical analysis was carried out using the Mann- Whitney U test.
Figure 6.6 shows that apoptotic figures were more frequent in rejecting grafts 
at days 4 (5.8 cells per HPF, SD 2.5) and 7 (8 cells per HPF, SD 1.8) than 
accepted allografts at both days 4 (3 cell per HPF, SD 1.6) and 7 (4.6 cells per 
HPF, SD 0.7) after transplant, reaching statistical significance at day 7 (P= 
0.03). This data is similar to that found by other groups studying apoptosis in 
liver and small bowel grafts where maximal apoptosis was found at day 7 in
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Figure 6.6 Apoptotic cells identified by TUNEL in heart 
grafts from R73 treated and rejecting animals. Lewis heart 
grafts were excised from DA recipient rats on days 4 and 7 
after transplant and snap frozen in liquid nitrogen. 5u cryostat 
histological sections were stained using the TUNEL technique 
and TUNEL+ cells counted and results expressed as the mean + 
SD of ten consecutivehigh power fields (x400) in 3-4 animals 
per group. Apoptotic figures weresignificantly more frequent in 
the rejecting grafts compared to R73 treated at day 7 post 
transplant. * Mann- Whitney U test, compared to R73 treated 
animals.
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rejecting allografts (Meyer et al, 1998). Other groups studying rejection in 
mouse heart allografts however, have described peak apoptotic levels at day 3 
post transplant with very few figures at day 7 (Bergese et al, 1997).
The tissue distribution of apoptotic cells also differed between rejecting and 
R73 treated grafts with apoptosis occurring randomly throughout the graft in 
rejecting animals and confined to cellular infiltrates in R73 treated grafts with 
virtually no apoptotic figures seen within normal myocardium (Figures 6.7- 
6.9).
172
A
t  >
Figure 6.7 Photomicographs of heart allografts removed from (A) 
an R73 treated recipient at day 7 post transplant and (B) an 
unmodified rejecting control animal (x250). Apototic cells detected 
by TUNEL are stained brown. Apoptosis in R73 treated hearts is 
confined to cellular infiltrates but found throughout the graft in 
rejecting animals.
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Figure 6.8 Photomicographs of heart allografts removed from (A) 
an R73 treated recipient at day 7 post transplant and (B) an 
unmodified rejecting control animal (x400). Apototic cells detected 
by TUNEL are stained brown.
Figure 6.9 Photomicographs of heart allografts removed from (A) 
an R73 treated recipient at day 4 post transplant and (B) an 
unmodified rejecting control animal (x400). Apototic cells detected 
by TUNEL are stained brown.
6:4 Discussion
Alpha/beta TCR +ve T cells are principal effector cells responsible for allograft 
rejection (Grade et al, 1990) and targeting these cells with R73 mAb is an 
effective method of abrogating the rejection process in the Lewis to DA rat 
strain combination. The experiments described in this chapter were carried out 
to determine whether apoptosis plays a role in prolonging graft survival after 
R73 treatment. The use of monoclonal antibodies has been shown to induce 
apoptosis in experimental models of tumour growth and anti-CD3 mAb has 
been shown to induce apoptosis in immature T cells (Trauth, et al, 1989, Smith 
et al, 1989). Conversely, cyclosporin A has been found to inhibit apoptosis in 
vitro (Anel et al, 1994).
Flow cytometric analysis was therefore carried out of PI stained lymph node 
cells from graft recipient animals treated with R73 mAb. Apoptotic activity was 
increased in the LNC of R73 treated animals compared to untreated graft 
recipients and normal DA rats particularly at day 7 after transplant. 
Interestingly, R73 treated animals who did not receive an allograft showed only 
baseline levels of apoptosis.
These observations suggest firstly that R73 triggers apoptosis in infiltrating 
lymphocytes and that this may, at least partly, be responsible for the 
prolongation of graft survival seen in this model. Secondly, the presence 
alloantigen as well as R73 mAb is required for apoptosis in this model. This can
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be explained by the observation made by other groups that only activated T 
cells are susceptible to TCR induced apoptosis (Van Parijs et al, 1996) and is 
supported by the observation here that apoptosis increases at day 7 post 
transplant in R73 treated animals, a time point when previously depleted T cell 
numbers are recovering. Thus the combination of TCR ligation by 
MHC+alloantigen and the presence of R73 appears to result in altered 
signalling through the TCR.CD3 complex resulting in apoptosis of the 
alloreactive T cell. The continued presence of alloantigen alone, however does 
not result in apoptosis in lymphocytes since only baseline levels of apoptotic 
activity are seen at day 100 after transplant, a time point where R73 is no 
longer detectable.
TUNEL labelling of apoptotic cells in heart allografts gave a contrasting 
picture to that found in lymph node cells. Apoptotic activity was higher in 
rejecting grafts with only rare apoptotic figures seen in allografts from R73 
treated animals. In addition, the apoptotic cells were mainly confined to groups 
of infiltrating cells and were absent from normal myocardium. This would 
suggest that apoptosis plays a different role in the graft and probably reflects 
destruction of allogeneic myocardial cells by cytotoxic T cells through the 
induction of apoptosis, a recognised mechanism of T cell killing (Hanabuchi et 
al, 1994). The lack of apoptotic figures in the grafts of R73 treated recipients 
may also be partly due to the reduced number of graft infiltrating T cells seen in 
this model.
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The increase in TUNEL+ cells in graft infiltrates at day 7 post transplant 
probably reflects an increase in not only target cell killing by T cells but also the 
apoptosis of alloreactive T cells themselves as a physiological method of 
limiting the immune response itself to the destroyed allograft.
In conclusion, apoptosis plays a complicated role in both allograft rejection and 
prolongation of graft survival in this model. The physiological role of apoptosis 
as a mechanism of cytotoxic T cell killing and as a way of limiting the immune 
response is seen in the grafts of unmodified graft recipients. A therapeutic role 
of apoptosis is demonstrated in the lymph nodes of R73 treated graft recipients 
where activated, alloreactive lymphocytes are deleted by apoptosis, induced 
most likely, by the combined signalling of R73 mAb and alloantigen through 
the T cell receptor.
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6:5 Summary
6:2 Flow cytometric analysis shows increased numbers of apoptotic cells in the 
lymph nodes of R73 treated recipients of a heart allograft day 7 post transplant 
compared to normal DA animals and recipients rejecting their grafts.
6:3 Labelling of apoptotic cells in heart grafts detected increased apoptotic 
activity in rejecting grafts compared to R73 treated grafts. In addition the 
apoptotic activity in rejecting grafts was confined to areas of cellular 
infiltration.
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CHAPTER SEVEN 
Final Discussion
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Discussion
The use of monoclonal antibodies either as an adjunct to chemical 
immunosuppression or to induce long term graft tolerance is currently of great 
interest. The experiments reported in this thesis attempt to clarify the 
mechanisms of action, potential benefits and possible drawbacks of using a 
monoclonal antibody directed at the a/p  T cell receptor.
In the initial experiments, R73 mAb was shown to prolong heart graft survival 
indefinitely in the Lewis-DA rat strain combination. An interesting new finding 
was that prolonged graft survival but not indefinite survival could be induced in 
other strain combinations. Other investigators have made similar observations 
in other models of transplantation, leading to the terms “high” and “low” 
responder strain combinations. The use of R73 mAb has been reported to 
induce long term heart graft acceptance in the BN-Lewis strain combination 
(Tsuchida et al, 1994), however permanent graft survival was not seen in this 
strain combination in the experiments reported here. These observation do not 
make the experiments in the Lewis-DA strain any less relevant, they simply 
imply that perhaps the immunological mechanisms responsible for graft 
tolerance are not different from other rat strains but are more easily activated in 
DA rats.
Several novel observations have been made in the subsequent experiments 
using R73 mAb in the Lewis-DA strain combination. The ability of DA rats to
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accept indefinitely a Lewis heart allograft in the absence of an intact thymus 
gland confirms that the R73 acts directly on the peripheral T cell pool and that 
recent thymic emigrants are not responsible for extension of graft survival. The 
observation that exogenous IL-12 administered after R73 treatment and heart 
grafting could diminish the effect of R73 again suggests that R73 acts by 
disabling the peripheral T cell pool though not permanently. It would have been 
interesting, if time allowed, to investigate the effect of administering other 
exogenous cytokines such as IL-2 in this model and perhaps anti-IL-4 mAb in 
the post transplant period to further clarify whether immune deviation plays a 
major role in prolonging graft survival after R73 treatment.
Further insights into the mechanism of action of R73 are illustrated by the in 
vitro experiments outlined in this thesis. R73 treatment induces peripheral T 
cell depletion in the early post transplant phase with recovery to 50% of normal 
by day 7 and almost complete recovery by day 21. The presence of 30-50% of 
the peripheral T cell pool in the early post transplant period and the ability of 
R73 to prolong graft survival even when the transplant is delayed to a point 
where R73 is present in low concentration on peripheral T cells suggests that 
R73 does not simply act by depletion of alloreactive cells and may in fact 
promote the development of regulatory or suppressor T cells (which may be y/8 
+ve T cells) or may render the remaining T cells anergic. It has been suggested 
that soluble anti-CD3 mAb mediated immunosuppression is, in part, due to 
alloreactive T cell inactivation (Smith and Bluestone, 1997). Further 
experiments would be required to clarify these points and it would be of value
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to repeat the flow cytometry to look for evidence of regulatory cells such as y/5 
T cells and CD25 +ve CD4 T cells in the early post transplant period. TCR 
modulation (shown by the experiments in Chapter 4) induced by R73 further 
supports the hypothesis that R73 acts by modifying the response of the 
remaining T cells to the graft.
The in vitro analysis of LNC harvested from R73 treated graft recipients 
outlined in Chapter 5 suggests that they proliferate poorly in the first four days 
after R73 treatment but proliferate normally by day 7. By contrast, however, 
IL-2 production by these cells is impaired even 100 days after transplantation. 
The presence of IL-2 has been shown to be critical for graft rejection in some 
models (Kirkman et al, 1985, Wood et al, 1993) and is the dominant cytokine 
responsible for clonal expansion of activated T cells and so impaired T cell help 
seems likely during the early phase post transplant in this model. Although the 
impaired ability of these cells to produce IL-2 and IFNy could suggest immune 
deviation towards a Th2 type response, the ability of these cells to produce IL- 
4 and IL-10 was not investigated due to the lack of a reliable assay in the lab at 
the time of these experiments but would be a valuable future experiment. 
Intragraft transcripts for Thl and Th2 cytokine genes were detected by RT- 
PCR in both R73 treated and rejecting grafts, though IL-2 and IFNy were less 
readily detected in heart grafts from R73 treated animals. These findings 
provide some evidence of a Thl to Th2 cytokine shift though this should be 
interpreted with caution. It is equally possible that it is the absence of IL-2, a
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strong barrier to the induction of tolerance, rather than Th2 polarisation that is 
responsible for prolonged graft survival in this model (Strom et al, 1996).
It would be interesting to carry out adoptive transfer experiments using LNC 
from R73 treated graft recipients, transferring the cells into naive DA hosts and 
then transplanting a Lewis heart graft without further treatment, to determine 
whether these cells could transfer immunity to the naive animal and so provide 
evidence as to whether they are indeed regulatory cells or simply unresponsive. 
It would also be valuable to investigate the intracellular signalling events which 
occur in these cells in the post transplant period in the light of recent work 
reported by Smith and Bluestone suggesting that anti-CD3 mAb may work by 
altering signalling through the TCR (Smith and Bluestone, 1997). Although the 
results above suggest that LNC from R73 treated graft recipients are unable to 
produce IL-2 normally even as long as 100 days after treatment, it would be 
important to test whether this results in long term unresponsiveness in vivo by 
carrying out a second allogeneic vascularised heart graft in animals who have 
accepted their first grafts permanently.
An alternative and novel mechanism for the action of R73 is suggested by the 
results shown in Chapter 6. Activation induced cell death (AICD) of T 
lymphocytes is a well characterised method of T cell death and is thought to 
contribute to the limitation of physiological immune responses. Repeated or 
excessive signalling through the T cell receptor is thought to induce apoptosis 
in activated T cells and this can be independent of the Fas system (Van Parijs et
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al, 1996). Using propidium iodide labelling of apoptotic LNC we demonstrated 
that cells in the lymph nodes of R73 treated graft recipients undergo apoptosis 
at a higher rate than that found in normal DA rats and animals rejecting their 
grafts. Interestingly, this was dependent not only on the presence of R73 but on 
a graft being present also. It would seem reasonable to propose that the 
combination of R73 and APC ligation results in altered intracellular signalling 
and activation of the apoptotic pathway.
Investigation of apoptosis in the heart grafts of R73 treated and rejecting 
animals provided interesting and seemingly paradoxical results. Apoptotic 
activity was increased in the grafts of rejecting animals compared to those 
transplanted under cover of R73 treatement. These results, however, illustrate 
the diverse role which apoptosis plays in biological systems. In the rejecting 
graft, it is likely that TUNEL demonstrated apoptosis of parenchymal cells 
mediated by infiltrating T cells in untreated animals, but FACS of PI stained 
lymph node cells showed apoptosis of alloreactive cells in the presence of R73 
illustrating activation induced cell death in the presence of an effective 
antibody.
The role of the Fas/FasL system in the initiation of apoptosis has been 
extensively investigated (Desbarats et al, 1998, Peter and Krammer, 1998). An 
attempt was made using flow cytometry during the above experiments to 
quantify any changes in Fas expression in LNC after R73 treatment. At the time 
of the experiments, a satisfactory anti-rat Fas mAb could not be found and we 
discovered using flow cytometry that the available anti-mouse preparations
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were cross reactive with other rat antigens as shown by a strongly positive 
signal in the negative control group of cells. It would be very interesting, 
however to look at Fas expression on R73 treated LNC at day 7 post transplant 
in the light of new mAb preparations being available.
The mechanisms underlying the action of anti-TCR monoclonal antibody are 
complex and diverse: depletion, anergy, immune deviation,
regulation/suppression and apoptosis. Further investigations as indicated above 
are required to fully elucidate these. This thesis does provide, however, a novel 
insight into these mechanisms and provides evidence for the potential efficacy 
of ant-TCR directed therapy in clinical practice. Although there are many 
aspects of anti-TCR mAb treatment which still need to be addressed, there is 
no doubt that that it could provide a useful tool for investigating the complex 
interactions of the T cell receptor and APC and for investigating the conditions 
required for allograft tolerance.
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